Analysis of the Temporal-Spatial Activation of Wnt-Signaling within Type 1/ Type 2 Immunity during Wound Healing by Ordieres Ruiz, Michelle Denise
 Analysis of the Temporal-Spatial Activation of Wnt-Signaling within 
Type 1/ Type 2 Immunity during Wound Healing 
 
 
Dissertation 
zur Erlangung des akademischen Grades 
Dr. med.  
an der Medizinischen Fakultät 
der Universität Leipzig 
 
 
eingereicht von:  
Michelle Denise Ordieres Ruiz 
 
Geburtsdatum / Geburtsort:  
02.06.1984 in Mexiko-Stadt 
 
angefertigt an /in:  
Universität Leipzig / Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie 
 
Betreuer:  
Prof. Dr. med. Jan C. Simon / Dr. rer. nat. Sandra Franz / Dr. rer. medic. Ruben A. Ferrer  
 
Gutachter: 
1. Prof. Dr. rer. nat. Michaela Schulz-Siegmund; Universität Leipzig; Institut für Pharmazie / 
Lehrstuhl für Pharmazeutische Technologie 
2. Prof. Dr. med. Stefan Langer; Universität Leipzig; Klinik und Poliklinik für Orthopädie, 
Unfallchirurgie und Plastische Chirurgie 
 
Einreichungsdatum: 30.08.2019 
Verteidigungsdatum: 05.03.2019 
 
Beschluss über die Verleihung des Doktorgrades vom: 19.03.2019 
  2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  3 
Table of contents 
LIST OF ABBREVIATIONS ................................................................................................... 5 
INDEX OF FIGURES ............................................................................................................... 7 
INDEX OF TABLES ................................................................................................................. 8 
SUMMARY ............................................................................................................................... 9 
1 INTRODUCTION ........................................................................................................ 11 
1.1 Cutaneous wound healing ............................................................................................... 11 
1.2 Phases of wound healing ................................................................................................. 11 
1.2.01 Inflammation ...................................................................................................... 11 
1.2.02 Proliferation ....................................................................................................... 13 
1.2.03 Remodeling ........................................................................................................ 16 
1.3 Wnt-signaling ................................................................................................................. 17 
1.3.01 Wnt-ligands biogenesis and receptors ................................................................. 17 
1.3.02 Canonical and non-canonical Wnt-signaling ....................................................... 20 
1.3.03 Canonical Wnt/ß-catenin signaling ..................................................................... 20 
1.4 Wound healing and canonical Wnt/ß-catenin signaling ................................................... 21 
2 AIMS OF THE STUDY................................................................................................ 25 
3 MATERIALS AND EXPERIMENTAL PROCEDURES ........................................... 27 
3.1 MATERIALS ................................................................................................................. 27 
3.1.01 Instruments......................................................................................................... 27 
3.1.02 Software ............................................................................................................. 27 
3.1.03 Websites............................................................................................................. 28 
3.1.04 Consumables ...................................................................................................... 28 
3.1.05 Media and Buffers .............................................................................................. 29 
3.1.06 Reagents............................................................................................................. 29 
3.1.07 Stimulation reagents ........................................................................................... 30 
3.1.08 Anesthesia and analgesia used for the full-thickness skin wound model .............. 30 
3.1.09 Kits .................................................................................................................... 30 
3.1.10 Quantitative reverse-transcription PCR primers .................................................. 31 
3.2 EXPERIMENTAL PROCEDURES ................................................................................ 32 
3.2.01 Mice ................................................................................................................... 32 
  4 
3.2.02 Cell Lines ........................................................................................................... 32 
3.2.03 Cell counting with trypan blue stain and hemocytometer method ........................ 32 
3.2.04 Preparation of murine H133WT immortalized primary keratinocytes cultures ..... 33 
3.2.05 Preparation of RAW264.7 murine macrophages cultures ..................................... 33 
3.2.06 Preparation of primary murine fibroblasts cultures .............................................. 33 
3.2.07 Type 1 and type 2 immunity cell stimulation ....................................................... 34 
3.2.08 Cell RNA isolation ............................................................................................. 34 
3.2.09 Mice wounding ................................................................................................... 35 
3.2.10 Whole skin tissue isolation.................................................................................. 36 
3.2.11 Epidermal and dermal tissue isolation ................................................................. 36 
3.2.12 Tissue RNA isolation .......................................................................................... 36 
3.2.13 cDNA synthesis .................................................................................................. 36 
3.2.14 Quantitative Real-Time PCR (qPCR) .................................................................. 37 
3.2.15 Statistical analysis .............................................................................................. 37 
4 EXPERIMENTAL RESULTS ..................................................................................... 39 
4.1 Canonical Wnt/ß-catenin signaling activity in different skin cell populations under type 1 
and type 2 immunity cytokines stimulation in vitro ......................................................... 39 
4.2 Canonical Wnt/ß-catenin signaling activity under type 1 and type 2 immunity conditions 
during wound healing in vivo .......................................................................................... 42 
4.3 Wnt-ligands expression in different skin cell populations under type 1 and type 2 immunity 
cytokines stimulation in vitro .......................................................................................... 44 
4.4 Wnt-ligands expression in epidermal and dermal fraction under type 1 and type 2 
immunity conditions in vivo ............................................................................................ 51 
5 DISCUSSION ................................................................................................................ 53 
6 CONCLUSIONS ........................................................................................................... 59 
7 PERSPECTIVES .......................................................................................................... 61 
8 REFERENCES ............................................................................................................. 63 
9 APPENDIX ................................................................................................................... 71 
9.1 Supplementary results ..................................................................................................... 71 
9.2 Erklärung über die eigenständige Abfassung der Arbeit................................................... 73 
9.3 Curriculum Vitae ............................................................................................................ 75 
9.4 Acknowledgments .......................................................................................................... 79 
  5 
List of abbreviations 
 ⍺-SMA ⍺-smooth muscle actin 
AKT Protein serine/threonine kinase 
APC Adenomatosis polyposis coli  
ARG1 Arginase 1 
BMP Bone morphogenetic protein  
DC Destruction complex 
DKK-1 Dickkopf-1 
DMSO Dimethyl sulphoxide 
ECM Extracellular matrix 
EGF Epidermal growth factor 
ER Endoplasmic reticulum 
ESCs Epidermal stem cells 
e.g. Exempli gratia 
FACS Fluorescence-activated cell sorting 
Fgf9 Fibroblast growth factor 9 
FZDs Frizzleds 
GSK3 Glycogen synthase kinase 3  
HF Hair follicle 
Hh Hedgehog 
Hz Hertz 
KLF4 Krüppel-like factor 4 
KRT9 Keratin 9 
iNOS Inducible nitric oxide synthase 
INF-γ Interferon γ 
IFE Interfollicular epidermis 
IFESCs Interfollicular epidermis stem cells 
IL-13 Interleukin-13 
IL-4 Interleukin-4  
i.p. Intraperitoneal 
LRP5/6 Low-density lipoprotein receptor-related protein 
Lef-1 Lymphoid enhancer binding factor-1 
LPS Lipopolysaccharide 
MACS Magnetic-activated cell sorting 
M-MLV R Maloney Murine Leukemia Virus Reverse Transcriptase  
MMPs  Matrix metalloproteinases  
M1 Classically activated macrophage 
M2 Alternatively activated macrophage 
JNK N-terminal kinase  
NK Natural killers cell 
NO Nitric oxide 
  6 
PCP Planar cell polarity 
PDGF Platelet derived growth factor 
PMNs Polymorphonuclear leukocytes 
PWD Post wound day 
rxn Reaction 
ROS Reactive oxygen species 
Relm-⍺ Resistin-like molecule alpha 
rpm Revolutions per minute 
RT Room temperature 
sFRPs Secreted frizzled-related proteins 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
Shh Sonic hedgehog 
SSc Systemic sclerosis 
Th1 T helper 1 cells 
Th2 T helper 2 cells 
Tcf-1  T-cell factor-1 
TGFß  Transforming growth factor β 
TNBS 2,4,6-trinitrobenzene sulfonic acid 
TNF Tumor necrosis factor 
VEGF-A Vascular endothelial growth factor A  
WIF Wnt inhibitory protein 
Wls Wntless Wnt-ligand secretion mediator 
WIHN Wound-induced hair neogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  7 
Index of figures 
Figure 1. Type 1 and type 2 immunity during wound healing.. .................................................. 13 
Figure 2. Reepithelization during wound healing. ..................................................................... 14 
Figure 3. Fibroblasts functions and canonical Wnt/ß-catenin signaling ...................................... 15 
Figure 4. Wnt-ligand biogenesis. .............................................................................................. 18 
Figure 5. Canonical Wnt/ß-catenin signaling in cells ................................................................. 21 
Figure 6. Full-thickness excisional wound model ...................................................................... 35 
Figure 7. Effect of type 1 and type 2 immunity cytokines on canonical Wnt/ß-catenin signaling 
activity in vitro .......................................................................................................... 40 
Figure 8. Effect of M1 and M2 polarization on canonical Wnt/ß-catenin signaling activation in 
vitro .......................................................................................................................... 41 
Figure 9. Kinetic of type 1 and type 2 immunity cytokines expression in wounded whole mice 
skin ........................................................................................................................... 42 
Figure 10. Purity of epidermal and dermal fractions after tissue separation ................................ 43 
Figure 11. Canonical Wnt/ß-catenin activity in epidermal and dermal fractions of wounds ........ 44 
Figure 12. Effect of type 1 and type 2 immunity on Wnt-ligands expression in immortalized 
keratinocytes, primary fibroblasts and RAW264.7 macrophages .............................. 48 
Figure 13. Wnt-ligand expression in M1 and M2 polarized macrophages .................................. 50 
Figure 14. Wnt-ligand expression in wounded epidermal and dermal fraction during early and 
late inflammatory phase of the wound healing.......................................................... 52 
Figure 15. Isolation of different skin cell populations from the dorsal skin of WT mice by 
fluorescence-activated cell sorting (FACS) .............................................................. 71 
 
 
 
 
 
 
 
 
 
 
 
 
  8 
Index of tables  
Table 1. Wnt-ligands function and temporal-spatial expression in different skin models. ........... 18 
Table 2. Instruments used for experimental procedures .............................................................. 27 
Table 3. Software used for experimental analysis ...................................................................... 27 
Table 4. Websites used for experimental procedures .................................................................. 28 
Table 5. Consumables used for experimental procedures ........................................................... 28 
Table 6. Media and buffers used for experimental procedures .................................................... 29 
Table 7. Reagents used for experimental procedures .................................................................. 29 
Table 8. Stimulation reagents used for generating cultures of fibroblast, RAW264.7 macrophages 
and immortalized keratinocytes ................................................................................... 30 
Table 9. Anesthesia and analgesia used for skin wounding in mice ............................................ 30 
Table 10. Kits used according to manufacturer’s instructions. .................................................... 30 
Table 11. Primer name, accession number, primer sequence, amplicon length and annealing 
temperature of each gene used in the present study. .................................................... 31 
Table 12. Components used for cDNA synthesis ....................................................................... 37 
Table 13. RNA template used for cDNA synthesis .................................................................... 37 
Table 14. Reagents for the amplification of the cDNA fragments .............................................. 37 
Table 15. Effect of type 1 immunity on Wnt-ligand gene expression in vitro ............................. 45 
Table 16. Effect of type 2 immunity on Wnt-ligand gene expression in vitro ............................. 46 
Table 17. Wnt-ligand expression in induced M1 and M2 macrophages cell line RAW264.7. ..... 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  9 
Summary 
Wnt/ß-catenin signaling and immunity during wound healing are required for adequate tissue 
formation and repair. Therefore, it is crucial to understand in which cells and when the pathway is 
activated and how immunity interacts with this process. The aim of this work was to analyze the 
temporal-spatial activation of the canonical Wnt/ß-catenin signaling and expression of 
Wnt-ligands in different cell populations of the skin under type 1 and type 2 cytokines and 
immunity contexts during wound healing. 
 
We analyzed the expression of Lef-1 (target gene of canonical Wnt/ß-catenin signaling) by q-PCR 
using a murine immortalized keratinocyte cell line, primary fibroblasts and RAW264.7 
macrophages. The cells were stimulated with two different cytokine conditions simulating type 1 
and type 2 immunity. We further investigated the expression of Lef-1 and Wnt-ligands in 
RAW264.7 macrophages after M1 and M2 polarization. Next, we used a mouse full-thickness 
skin wound model to investigate canonical Wnt/ß-catenin signaling and Wnt-ligands in vivo at 
different time points corresponding to the early and late phases of wound healing when type 1 and 
type 2 immunity predominate. 
 
In vitro results showed that Lef-1 and several Wnt-ligands were upregulated in keratinocytes and 
fibroblasts under type 2 immunity conditions, whereas no Lef-1 induction was found in RAW264 
macrophages. However, the Wnt-ligands (Wnt-5a, Wnt-7a, Wn-10a, Wnt-10b, Wnt-11 and 
Wnt-16) were downregulated in RAW264.7 macrophages under type 2 immunity conditions. In 
contrast, Wnt-ligands (Wnt-2a, Wnt-3a, Wnt-7a, Wnt-10a, Wnt-10b, Wnt-11 and Wnt-16) were 
upregulated in M1 macrophages. In vivo we found that Lef-1 was upregulated in both epidermal 
and dermal fractions also exclusively during the late inflammatory phase, dominated by type 2 
immunity. Although, most of the Wnt-ligands (Wnt-2a, Wnt-5a, Wnt-5b and Wnt-11) were also 
upregulated under a type 2 immunity context, we found that only Wnt-10a was upregulated under 
type 1 immunity conditions in both epidermal and dermal fractions.  
 
Our findings indicate that the canonical Wnt/ß-catenin signaling and Wnt-ligands are regulated by 
immunity and macrophage polarization. In keratinocytes and fibroblasts, we observed a favoring 
Wnt-activity and Wnt-ligand expression under type 2 immunity conditions. Future studies should 
clarify in vivo the role of macrophages on the canonical Wnt/ß-catenin signaling activation during 
wound healing, focusing on the modulation of Wnt-signaling and its ligands in distinct cell types 
during wound healing. 
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1 INTRODUCTION 
In Germany and other industrialized countries the incidence and prevalence of impaired wound 
healing is increasing due to the rise of risk factors, such as diabetes, obesity, surgery, trauma and 
aging of the population and represents a serious public health concern [1][2][3]. Furthermore, 
impaired wound healing has a direct impact on the patients’ quality of life and demands 
substantial healthcare costs [4]. Despite numerous investigations, the underlying mechanisms of 
wound healing are still not fully clarified. A deeper understanding of the interactions between the 
involved cells, growth factors and cytokines are likely to reveal new therapeutic targets for the 
modulation of the wound healing process. 
 
1.1 Cutaneous wound healing 
Wound healing after injury is a preserved survival mechanism and an intrinsic property of all 
multicellular organisms [4]. The healing process is dynamic and involves cell differentiation, 
migration, proliferation and apoptosis. It is organized through complex signaling pathways 
between cells and multidirectional interactions between growth factors and cytokines [5]. The 
ultimate result of this process is the scar, which is characterized by a disorganized extracellular 
matrix [6], a lack of skin appendages such as sweat glands and hair follicles and reduced 
functionality [7][8]. Any dysregulation of the mechanisms involved in the process might cause 
impaired wound healing, resulting either in non-healing wounds (chronic wounds) or excessive 
scarring (hypertrophic or keloid scar) [6]. The wound healing process can be subdivided in three 
main overlapping phases, which are explained in detail in the following section. 
 
1.2 Phases of wound healing 
1.2.01 Inflammation  
Immediately after injury the vascular endothelium constricts. Consequently, the coagulation 
cascade is initiated and platelets secrete fibrin, which promotes the infiltration of mast cells, 
neutrophils, polymorphonuclear leukocytes and monocytes [6]. Meanwhile, the innate immune 
system initiates the activation of an inflammatory program in response to tissue hypoxia and 
pathogen contamination [6][9]. 
 
Neutrophils and macrophages are the main cell populations dominating the early inflammatory 
phase of wound healing. The major function of neutrophils is to remove bacteria and recruit 
monocytes from the blood which then in the tissue differentiate into macrophages [6]. 
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Macrophages are a highly heterogeneous cell population showing different phenotypes with 
different specific functions. In addition to their innate phagocytic and antimicrobial activity, 
macrophages are also involved in wound repair by modulating the transition from a pro- to an 
anti-inflammatory response [10]. In that way, macrophages influence the duration of the 
inflammatory phase by changing their phenotype in response to local microenvironmental signals 
[11]. The pro-inflammatory phenotype has been schematically defined as an M1 macrophage 
state, whereas the anti-inflammatory and pro-repair phenotype is called M2 in analogy to the Th1 
and Th2 polarization of T-cells. M1 macrophages, also known as classical activated macrophages, 
are essential to protect the body from foreign microorganisms through toxic effectors [12], but 
these can also cause collateral tissue damage [10]. The pro-inflammatory response of M1 
macrophages is antagonized by anti-inflammatory M2 macrophages, also known as alternatively 
activated macrophages. Besides anti-inflammatory factors which promote the resolution of 
inflammation, M2 macrophages also secrete morphogenic cues required for cell differentiation, 
neovascularization, granulation tissue maturation and extracellular matrix assembly and 
remodeling [11]. The resolution of inflammation is mandatory to begin tissue repair, otherwise a 
prolonged inflammatory phase may result in chronic wounds [13]. 
 
The immune system and tissue resident cells interact with macrophages through the release of 
cytokines which trigger M1 or M2 phenotype differentiation [11]. During the early inflammatory 
phase, neutrophils, T-helper 1 cells and the mononuclear phagocytic system (MPS), composed of 
monocytes and tissue macrophages, induce a pro-inflammatory type 1 immunity response 
[14][15]. Neutrophils, macrophages and T-helper 1 cells secrete cytokines, such as IL-1ß, TNFa 
and IFN-g into the wound microenvironment to mediate this event [16] [15]. Thereafter, TNFa 
and IFN-g in combination with bacterial components like lipopolysaccharides (LPS) stimulate the 
differentiation of macrophages into the M1 phenotype [11]. Inducible nitric-oxide synthase 
(iNOS) is then expressed by M1 macrophages in order to provide defense from bacteria, protozoa 
or viruses through the production of nitric oxide (NO) and reactive oxygen species (ROS) among 
others [10] (Figure 1). 
 
In the late inflammatory phase, eosinophils, mast cells, basophils and T-helper 2 cells secrete 
cytokines such as IL-4 and IL-13 which belong to the type-2 immunity [14]. The release of IL-4 
and IL-13 triggers the differentiation of macrophages into the M2 phenotype. Thereby, the 
inflammatory response decreases and the subsequent wound healing phase initiates. After 
polarization, M2 macrophages express Arginase 1, the mannose receptor CD206 and the IL-4 
receptor a-chain among others. In response to type-2-cell mediated immunity, M2 macrophages 
secrete molecules like IL-10, IL-13, TGFß and Relm-a, which regulate the proliferation and 
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organization of new skin tissue. For example, the production of Relm-a controls the stability of 
the extracellular matrix (ECM) by directing collagen cross-linking and fibrillogenesis via lysyl 
hydroxylase 2 (LH2) in fibroblasts [17] (Figure 1). 
 
 
Figure 1. Type 1 and type 2 immunity during wound healing. Type 1 immunity promotes host 
protection against potential pathogens through the secretion of pro-inflammatory cytokines (IL-1ß, TNFa 
and IFNg), nitric oxide (NO) and reactive oxygen species (ROS). Type 2 immunity promotes tissue 
homeostasis and repair through the secretion of anti-inflammatory cytokines (IL-4, IL-13, Relm-a, PDGF 
and TGFß). 
 
1.2.02 Proliferation  
During the proliferative phase, neovascularization occurs within the dermis while the epidermis 
and dermis are restored [6]. In the epidermis, interfollicular and hair follicle stem cells proliferate, 
differentiate and migrate to close the wound gap [18]. Keratinocyte migration is facilitated by 
matrix metalloproteinases (MMPs) and collagenases, which break down the desmosomes which 
bind them together [18]. Once the keratinocytes reach the wound bed they begin to proliferate and 
differentiate. Different keratinocyte subpopulations have distinct functions during reepithelization 
[19]. Recently, a study at the tail epidermis of mice identified two epidermal zones which 
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performed distinct functions during wound repair [18]. The first zone, named leading edge, is 
composed of non-proliferative keratinocytes and acts as a scaffold, facilitating the proliferation 
and migration of the stem cells. In this zone, cell migration is regulated through the expression of 
different genes, such as  Mmp9, Mmp13, Mmp1b and Wnt-5a, which encode proteins facilitating 
this process [18]. The second zone, named the proliferative hub, is composed of the interfollicular 
epidermis (IFE) and hair follicle (HF) derived stem cells which proliferate and migrate towards 
the center of the wound [18] (Figure 2). The renewal of epidermal stem cells populations is in 
various ways controlled by Wnt-signaling [20]. 
 
 
 
Figure 2. Reepithelization during wound healing. Keratinocytes during wound healing performing 
different functions within distinct epidermal zones. Keratinocytes of the leading edge (LE) elongate their 
cell shape and migrate toward the wound center, acting as a scaffold for newly formed keratinocytes. 
MMPs and Wnt-5a, among other proteins, regulate cell migration during reepithelization. Keratinocytes of 
the proliferative area increase the proliferation rate of IFE and HF-derived stem cells. The arrows represent 
the migration direction during proliferation. (Adapted from [18]). 
 
The wounded dermis is restored through the deposition of granulation tissue, which contains 
immune cells, newly formed blood vessels and ECM [21][22]. The ECM, mainly composed of 
type-III collagen, elastin and fibrin, is synthesized by fibroblasts [6] under the effect of growth 
factors such as TGFß and PDGF. TGFß is mainly released by M2 macrophages but also from 
platelets, keratinocytes and fibroblasts [23]. In the human dermis at least four distinct 
subpopulations of fibroblasts (papillary fibroblasts, reticular fibroblasts, preadipocytes and 
Wnt-5a 
MMPs 
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pericytes) have been identified [24]. During wound healing, these subpopulations perform 
different functions depending on their site of origin [25]. The papillary fibroblasts, which are 
located in the upper dermis, regulate the piloerection and new hair follicle (HF) formation, while 
the reticular fibroblasts, which are located in the lower dermis, synthesize collagen and other 
elastic fibers to reconstruct the extracellular matrix of the connective tissue [25], being also 
responsible for the bulk production of scar tissue in pathological situations [26]. The lower dermis 
fibroblasts lineage also gives rise to preadipocytes and pericytes-blood vessel-associated 
fibroblasts [24]. These functions of fibroblasts in the dermis are mediated through the sustained 
activation of epidermal canonical Wnt/ß-catenin signaling [27]. 
 
Figure 3. Fibroblasts functions and canonical Wnt/ß-catenin signaling. Sustained activation of 
epidermal Wnt/ß-catenin signaling mediates in papillary fibroblasts hair follicle formation, in reticular 
fibroblasts the ECM synthesis. Wnt-signaling over-regulation causes fibrosis with a diminished dermal 
adipose layer. (Adapted from [28]). 
 
Moreover, reticular fibroblasts differentiate into myofibroblasts, which are responsible for the 
contraction of the wound and determine the quality of the scar, depending on their upregulation of 
a-SMA (alpha-smooth muscle action). Differentiation into myofibroblasts is triggered by type 
2-cell mediated cytokines, such as IL-4, IL-13 and TGFß. Among those, TGFß is the most potent 
growth factor for myofibroblast genesis and in its absence, myofibroblasts lose their function and 
undergo apotosis [29]. Myofibroblast activation by TGFß is mainly induced via canonical Smad 
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2/3 but also via non-canonical JNK signaling pathways [30]. Furthermore, TGFß pathway and 
canonical Wnt/ß-catenin signaling interact with each other regulating myofibroblasts function in 
the synthesis of ECM [31]. However, this specific mechanism is not yet fully elucidated [32]. 
Once the tissue integrity is restored, the activity of myofibroblasts is reduced. If myofibroblasts 
remain active after the closure of the wound an overproduction of ECM with excessive wound 
contraction and tissue fibrosis occurs [21]. Interestingly, a recent study has demonstrated that 
myofibroblasts during wound healing are capable to transdifferentiate into adipocytes via bone 
morphogenetic protein signaling (BMP) [33]. This evidence shows the plasticity of fibroblasts 
which can change their identity and function according to the secreted signals during the wound 
healing process.  
 
1.2.03 Remodeling 
The remodeling phase starts 2-3 weeks after injury in humans and can last up to one year. During 
this last phase, fibroblasts remodel the ECM through the secretion of matrix metalloproteinases. 
Thereby, type-III collagen is replaced with type-I collagen [6] and the wound healing related 
processes terminate. Finally, most of the macrophages, endothelial cells and myofibroblasts 
undergo apoptosis and are no longer present in the wound site [6]. 
 
Cell signaling dysregulations during any of the phases of the wound healing process may result in 
non-healing (e.g., chronic wounds), excessive repair (e.g., fibrosis) or regeneration, as 
demonstrated by Ito et al., who showed that hair follicles regenerated when large excisional 
wounds were inflicted on the back of an adult mouse in a wound induced hair follicle neogenesis 
(WIHN) model [34]. In humans, the ability of the skin to regenerate has been demonstrated only 
during fetal development [35]. Interestingly, the inflammatory response and expression of TGFß 
was significantly reduced in instances of regeneration. Furthermore, higher concentrations of 
hyaluronic acid and type-III collagen in comparison to postnatal wound healing were found 
[36][37]. Numerous key signaling pathways (e.g., TGFß, Hedgehog, Notch and Wnt/ß-catenin) 
which are involved during the embryological skin development are also activated during adult 
wound repair. These signaling pathways mediate cell behavior during reepithelization, ECM 
production, angiogenesis and hair follicle regeneration [7]. Therefore, an improved understanding 
of cell signaling pathways that regulate wound healing is a prerequisite for the development of 
novel treatments for its outcome modulation. 
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1.3 Wnt-signaling 
An effective therapy to treat impaired wound healing is not yet available, partly because the 
underlying mechanisms are not yet fully explored. However, in recent years molecular biology 
has made significant breakthroughs in the discovery of key signaling pathways activated during 
wound healing. One key cellular pathway during wound healing and regeneration is the canonical 
Wnt/ß-catenin signaling. It has attracted particular interest because its activation regulates cell 
differentiation, migration and proliferation in the wound [38]. The pathway mediates epidermal 
stem cells self-renewal [39] and fibroblast proliferation, which ultimately affects the wound 
healing outcome [40]. Furthermore, a prolonged and sustained canonical Wnt/ß-catenin activity 
leads to fibrosis by upregulating the expression of extracellular matrix protein-coding genes 
through interaction with the TGFß pathway [41]. Despite the known implications of the canonical 
Wnt/ß-catenin signaling during tissue repair, more investigations are needed to unravel its role 
during tissue repair. For example, it is not yet well understood in which specific cell populations 
and at which time points during cutaneous wound healing canonical Wnt/ß-catenin signaling is 
activated. Moreover, both type 1 and type 2 immunity might influence Wnt-signaling activity and 
potential interventions targeting this pathway might affect immune events that are fundamental 
for wound healing.  
 
The Wnt signaling pathway is a main regulator of cellular development across the animal 
kingdom from metazoan to mammals [42][43]. The first mammalian Wnt gene Int1, later 
renamed as Wnt1, was discovered by research on oncogenic retroviruses and was identified as an 
extracellular growth factor [44]. Further research revealed its function on human cancer, in 
embryonic development and in tissue repair [44], in which it orchestrates cell differentiation, 
proliferation and migration [42]. Not surprisingly, its deregulation results in both impaired wound 
healing, such as hypertrophic and keloid scars, and in the development of tumors [45]. 
 
1.3.01 Wnt-ligands biogenesis and receptors 
In mammals the Wnt pathway is composed of 19 Wnt-ligand proteins rich in cysteine, which are 
modified in the endoplasmic reticulum by the attachment of a lipid, termed palmitoleic acid [46] 
[47]. The lipid allows the Wnt protein to bind to the receptor and provides it with hydrophobic 
properties [48]. This biochemical conformation may confer restriction during signaling and may 
explain the range of action of the Wnt-ligand proteins, which is limited to neighboring cells [42]. 
As a final maturation step, the lipid modified form of the Wnt-ligand binds to Wntless/Evi (Wls), 
a cargo protein, to be secreted into the ECM [42] (Figure 4). 
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Figure 4. Wnt-ligand biogenesis. Wnt-ligands are generated and modified by the attaching of a lipid in the 
endoplasmic reticulum. Then, in the Golgi apparatus the ligand binds through the lipid to Wntless/Evi 
(Wls), a cargo protein that transports the Wnt-ligand into the ECM. Once liberated into the ECM 
presumably as an exocytic vesicle, the Wnt-ligand lipid complex binds to its Frizzled (FZD) receptor. 
(Adapted from [42]). 
 
As mentioned before, the Wnt-ligand proteins act as intercellular growth factors by transmitting 
signals through a cell surface receptor complex composed of two molecules, Frizzled (FZD) and 
low-density lipoprotein receptor-related protein 5/6 (LRP5/6) (Figure 5). Until now, ten different 
human Frizzled receptors are known. As a result of its activation, cells undergo changes in gene 
expression, cytoskeleton and mitotic spindle. The activity of the Wnt signaling pathway is 
regulated by extracellular inhibitors that antagonize the Wnt-ligands, such as Palmitoleoyl-Protein 
Carboxylesterase (NOTUM), Dickkopf-1 (DKK-1), Sclerostin, secreted FZD-related proteins and 
Wnt inhibitor factor (WIF) [42]. During wound healing, the expression and function of the 
Wnt-ligands has not yet been sufficiently explored. Therefore, little is known about its functions. 
An overview of what is known about Wnt-ligands during skin development and wound healing is 
provided in Table 1. 
 
Table 1. Wnt-ligands function and temporal-spatial expression in different skin models. 
Ligand Function Temporal-spatial activity Model Ref. 
Wnt-1  Participates in skin 
fibrosis  
 Skin biopsies from SSc patients  [49] 
 Not identified in wounded 
tissue and normal skin  
2 cm full-thickness whole skin 
incisions  
[50] 
Wnt-2a Overexpression 
promotes hair follicle 
regeneration 
Expressed in fibroblasts 
(PWD12 -PWD14)  
1.2 × 1.2 cm2 full-thickness 
skin excision wounds  
[51] 
Wnt-3  Ubiquitously detected at 
every time point 
(PWD1-PWD21) 
2 cm full-thickness whole skin 
incisions  
[50] 
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Wnt-4  Expressed in epithelial 
suprabasal cells 
(PWD3-PWD5)  
2 cm full-thickness whole skin 
incisions 
[50] 
Expressed in fibroblasts-like 
cells (PWD5-PWD7) 
2 cm full-thickness whole skin 
incisions 
[50] 
Ubiquitous expression in hair 
follicles 
2 cm full-thickness whole skin 
incisions 
[50] 
Expressed in IFE stem cells Full-thickness skin biopsy 
punch wound (2 mm-plantar 
epidermis, 3 mm-tail epidermis, 
4mm -dorsal skin) 
[39] 
Wnt-5a Stimulates G-protein 
dependent Ca2+ 
signaling machinery. 
Counteracts canonical 
Wnt/ß-catenin signaling 
Expression localize to hair 
follicles and sebaceous 
glands 
2 cm full-thickness whole skin 
incisions  
[50] 
Expressed in lymphocytes 2 cm full-thickness whole skin 
incisions 
[50] 
 Involved in wound 
remodeling (peak at PWD21 
and decreases at PWD28) 
1.5 cm2 full-thickness wound, 
covered with Tegaderm, 3M 
[52] 
Cytoskeletal 
reorganization and cell 
migration  
Expressed in the leading edge 
of the epidermis (PWD4 – 
PWD7) 
3 mm biopsy from mice tail 
epidermis  
[18] 
Activates non-canonical 
Wnt-signaling 
Expressed in the upper 
dermis or dermal condensate 
Mice embryos (development) [53] 
Wnt-7a  Weak expression in the 
epidermis 
Mouse embryos  
(development) 
[53] 
Maintains the 
hair-follicle-inducing 
capacity of dermal 
papilla cells 
Overexpression results in 
increased numbers of hair 
follicles 
Krt1-14-Wnt7a transgenic mice 
(hair cycling) 
[34] 
Wnt-10a First epithelial signal 
operating in hair follicle 
morphogenesis 
Expressed in hair follicles 
placodes 
Mouse embryos  
(development) 
[53] 
Epithelial proliferation  Expressed in IFE stem cells Full-thickness skin biopsy 
punch wound (2 mm-plantar 
epidermis, 3 mm-tail epidermis, 
4mm-dorsal skin) 
[39] 
[54] 
Wnt-10b Epithelial cells 
regeneration  
Present during early phases of 
healing (PWD1-PWD3) in 
epithelial cells 
2 cm full-thickness whole skin 
incisions. skin 
[50] 
 Expressed in hair follicle 
placodes 
Mouse embryos (development) [53] 
 Expressed in regenerated hair 
follicles 
1 cm2 square of full-thickness 
skin excision 
[34] 
Participates in fibrosis   Skin biopsies from SSc patients [49] 
Wnt-11 Promotes non-canonical 
calcium Wnt-signaling 
pathway 
Involved in wound 
remodeling (peak at PWD21, 
decreased at PWD28) 
1.5 cm2 full-thickness wound, 
covered with dressing 
(Tegaderm, 3M) 
[52] 
 Expressed in outer layers of 
anagen hair follicles  
Mouse embryos (development) [53] 
Myofibroblasts 
apoptosis  
 In vitro organ culture (palatal-
shelves) 
[55] 
Wnt-16  Very weak signal in the 
epidermis.  
Mouse embryos (development) [53] 
PWD= post wound days, SSc= systemic sclerosis, IFE= interfollicular epidermis 
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1.3.02 Canonical and non-canonical Wnt-signaling 
The Wnt signaling diversifies into three main branches according to their function: 1. the 
canonical Wnt/ß-catenin pathway, which activates target genes in the nucleus; 2. the 
non-canonical planar cell polarity pathway, which involves jun N-terminal kinase (JNK) and 
cytoskeletal rearrangements; and 3. the non-canonical Wnt/Ca2+ pathway, which regulates Ca2+ 
efflux from the endoplasmic reticulum acting as a second messenger [40]. These three 
Wnt-signaling branches are activated through Wnt-ligands and involved in the wound healing 
process. However, it is mainly the canonical Wnt/ß-catenin pathway which orchestrates cell 
proliferation and differentiation during wound healing by upregulating the T-cell factor 
transcription complex (TCF) target genes, such as Lef-1, Axin2, TGF-ß1, Hedgehog (Hh) and 
DKK-1 [56][51][57]. On the other hand, the non-canonical Wnt signaling pathways regulate cell 
migration and polarization during wound healing. Furthermore, they can also antagonize the 
ß-catenin dependent transcription through the secretion of Wnt-ligands which act as regulatory 
factors of the canonical Wnt/ß-catenin signaling [58][59]. 
 
1.3.03 Canonical Wnt/ß-catenin signaling 
The canonical Wnt/ß-catenin signaling cascade is initiated by a Wnt-ligand binding the cell 
surface receptor. This causes the translocation of cytoplasmic stabilized ß-catenin into the 
nucleus. Inside the nucleus, ß-catenin binds to TCF and promotes the upregulation of TCF target 
genes. In the absence of a Wnt-ligand, ß-catenin is degraded in the cytoplasm by a complex of 
proteins called the destruction complex (DC), which is composed of Axin, adenomatosis 
polyposis coli (APC), glycogen synthase kinase 3 (GSK3), two active serine-threonine kinases 
(CK1a and GSK3ß) and E3-ubiquitin ligase ß-TrCP. The phosphorylation by CK1a/GSK3-ß and 
ubiquitination by TrCP are required for the proteasomal degradation of ß-catenin. Therefore, 
ß-catenin is unable to accumulate and cannot translocate into the nucleus. However, when a 
Wnt-ligand binds the receptor, the DC dissociates, causing the accumulation of ß-catenin in the 
cytoplasm with consequent translocation into the nucleus. Unfortunately, the cellular source of 
the Wnt-ligands required for Wnt/ß-catenin activation in the skin is still unknown [42] (Figure 5). 
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Figure 5. Canonical 
Wnt/ß-catenin signaling in 
cells. Left: In the absence of 
Wnt-ligand protein, ß-
catenin is degraded in the 
cytoplasm by a complex of 
proteins (DC). The TCF is 
inactive, by binding to the 
repressor Groucho. Right: 
Wnt-ligand binding to 
receptor FZD and 
co-receptor LRP. The DC 
dissociates and ß-catenin 
accumulates in the 
cytoplasm with subsequently 
translocation into the 
nucleus. ß-catenin binds to 
TCF transcriptional factor 
and enables upregulation of 
target genes. (Adapted from 
[42]) 
 
 
1.4 Wound healing and canonical Wnt/ß-catenin signaling  
The canonical Wnt/ß-catenin signaling is present in all three phases of wound healing [60]. 
However, its activity is increased during the proliferative phase. Wnt activation is involved in the 
repair of both epidermis and dermis [41] and its outcome depends on which cell population gets 
activated and at which niche this population is located [27]. 
 
In the epidermis, Wnt/ß-catenin mediates two different cell types. The first are non-proliferative 
keratinocytes from the leading edge of the wound (Figure 2). The second are stem cell 
populations from the interfollicular epidermis (IFE) and the hair follicle (HF) bulge region [18]. 
Wnt-signaling regulates the migration of the non-proliferative keratinocytes from the leading edge 
towards the center of the wound in which high levels of Wnt-5a protein are expressed [18] 
(Figure 2). In the interfollicular epidermis, Wnt activation controls the heterogeneity and 
proliferation rate of the IFE stem cells [39][19]. When IFE stem cells become activated they give 
rise to new keratinocytes which are needed to close the wound [18]. In the hair follicle bulge 
region the canonical Wnt/ß-catenin signaling mediates the morphogenesis of hair follicles 
[61][62]. It has been demonstrated that an overexpression of the canonical Wnt/ß-catenin during 
the wound healing promotes the neogenesis of hair follicles [63]. In contrast, absence of the 
canonical Wnt/ß-catenin signaling in IFE stem cells decreased the proliferation rate of the 
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keratinocytes in the basal layer [64]. Furthermore, the absence in HF stem cells leads to the loss 
of hair follicles [27]. 
 
The epidermal Wnt/ß-catenin pathway mediates also distinct fibroblast subpopulations in the 
underlying dermis via paracrine signaling [27]. For example, a sustained epidermal Wnt/ß-catenin 
signaling stimulates the proliferation of dermal papillary fibroblasts via the epidermal Sonic 
Hedgehog (Shh) pathway, the signal expands through the stem cell niche and induces the 
formation of ectopic hair follicles, whereas in the reticular fibroblasts subpopulation it stimulates 
the proliferation, differentiation and ECM production through the activation of the TGF-ß2 
pathway [27] (Figure 3). 
 
While a stabilized canonical Wnt/ß-catenin activity during the proliferative phase is crucial for 
successful wound healing, a prolonged activity causes fibrosis and excessive scar formation 
[65][66]. This is explained through the interaction of TGF-ß1 with the canonical Wnt/ß-catenin 
pathway. TGF-ß1 indirectly activates the canonical Wnt/ß-catenin signaling in fibroblasts by 
decreasing the expression of DKK-1, an antagonist of the Wnt/ß-catenin signaling [49]. In 
particular, the Wnt-ligands Wnt-1 and Wnt-10b were overexpressed, increasing the levels of 
aSMA, which induced the differentiation of fibroblasts into myofibroblast [49]. The pro-fibrotic 
effect of increased canonical Wnt/ß-catenin signaling activity has been also demonstrated in the 
kidney [67], lung [68] and liver [69]. In transgenic mice, which overexpressed the Wnt/ß-catenin 
inhibitor DKK-1, bleomycin-induced fibrosis was prevented. However, topical application of 
DKK-1 in a full-thickness excisional model inhibited the regeneration of tissue [64]. This 
evidence highlights the complexity of the canonical Wnt/ß-catenin signaling and suggests that a 
modulation should be performed at specific time points and in a cell-specific manner. 
 
It is known that the autocrine canonical Wnt/ß-catenin signaling first regulates the self-renewal, 
proliferation, differentiation and migration of keratinocytes in the epidermis [18][19]. 
Furthermore, it was shown that Wnt-ligands are broadly expressed in the epidermis and that these 
epidermal Wnt-ligands mediate the proliferation of fibroblasts in the underlying dermis [70]. 
Moreover, the absence of Wnt/ß-catenin signaling in the dermis caused abnormalities in the 
epidermal hair follicle development and absence of the canonical Wnt/ß-catenin signaling in the 
epidermis [70]. The findings of these studies suggest a cross-talk of the canonical Wnt/ß-catenin 
signaling during the proliferation phase of wound healing between the epidermis and dermis.  
 
The Wnt/ß-catenin signaling was also shown to promote the regeneration of skin appendages in 
large wounds (>1 cm in diameter) in a wound-induced hair follicle neogenesis (WINH) model 
[34]. Moreover, another study revealed the role of the immune system as an initiator of the 
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canonical Wnt/ß-catenin signaling during the regeneration of hair follicles [51]. More precisely, 
the fibroblast growth factor 9 (Fgf9), produced by gd T-cells, activated the canonical 
Wnt/ß-catenin signaling in dermal fibroblasts [51]. A further study demonstrated that adipocytes 
regenerated in the presence of Wnt-ligands, supporting that canonical Wnt/ß-catenin signaling is a 
crucial mediator for tissue regeneration [33]. 
 
The canonical Wnt/ß-catenin signaling pathway is a promising target to promote tissue 
regeneration and reduce fibrosis during wound healing. Through the modulation of 
Wnt-signaling, several studies have demonstrated improved tissue repair outcomes. For example, 
a study in mice showed that the systemic temporary inhibition of Wnt-signaling after myocardial 
infarct reduced adverse remodeling by inhibition of myofibroblast proliferation and decreased 
Collagen I expression [71]. An earlier study from the same authors showed that inhibition of 
Wnt-signaling with topical application of small-molecule Wnt-inhibitors can reduce fibrosis and 
promote regenerative cutaneous wound repair [72]. Furthermore, a study in diabetic rats showed 
that the promotion of Wnt-activation by sequestering sclerostin, an inhibitor of Wnt-signaling, 
improved the regeneration of bone tissue after injury [73].  
 
Although it has become clear that canonical Wnt/ß-catenin activation has essential implications 
on the skin regeneration and wound healing, it is still unclear in which specific cell populations 
and at which time points the activation occurs. Moreover, further wound healing studies are 
needed to explore the expression and functions of the Wnt-ligands at specific time points and to 
clarify how immunity (type 1 and type 2) interacts with the canonical Wnt/ß-catenin signaling. 
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2 AIMS OF THE STUDY 
With the final goal to understand how modulation of canonical Wnt/ß-catenin signaling can 
improve skin repair during wound healing, it is first necessary to investigate the temporal-spatial 
activation of this signaling pathway throughout the wound healing process with special focus on 
the phases of type 1 and type 2 immunity, which are important regulatory checkpoints for tissue 
repair. 
 
The first aim of this study is to analyze the activation of the canonical Wnt/ß-catenin signaling in 
relevant cell populations of the skin compartments. Therefore, using murine keratinocytes, 
fibroblasts and RAW264.7 macrophages the following objectives were addressed in vitro: 
1. To determine whether type 1 and type 2 immunity regulates the activation of the canonical 
Wnt/ß-catenin signaling. 
2. To explore whether canonical Wnt/ß-catenin activation takes place in polarized M1 and 
M2 macrophages. 
 
The second aim of this study is to define the potential time points for specific Wnt-modulation in 
the epidermal and dermal compartment of the skin during wound healing. Therefore, using a full-
thickness wound model in mice the following objectives were addressed in vivo: 
1. To determine the time points in which type 1 and type 2 immunity cytokines are 
upregulated. 
2. To investigate whether canonical Wnt/ß-catenin signaling is activated within the 
epidermis and dermis under type 1 and type 2 immunity time points. 
 
The third aim of this study is to determine the role of type 1 and type 2 immunity on the 
expression of Wnt-ligands in vitro and in vivo: 
1. To determine which Wnt-ligands are upregulated in keratinocytes, fibroblasts and 
macrophages under type 1 and type 2 immunity cytokines stimulation. 
2. To determine which Wnt-ligands are upregulated in M1 / M2 polarized macrophages. 
3. To determine which Wnt-ligands are upregulated in the dermal and epidermal 
compartment during the early (type 1 immunity) and late (type 2 immunity) wound 
healing phases. 
 
 
  26 
 
  
  27 
3 MATERIALS AND EXPERIMENTAL PROCEDURES 
3.1 MATERIALS 
3.1.01 Instruments 
Table 2. Instruments used for experimental procedures 
Apparatus Company 
 
Cell culture CO2 incubator New Brunswick, Galaxy 
170  Eppendorf AG, DE 
Cell culture CO2 incubator with magnetic stirrer  Binder GmbH, DE 
Centrifuge 5810R  Eppendorf AG, DE 
Fluorescence microscope BZ-900 – Biorevo Keyence GmbH, DE 
Freezer -20 °C, Comfort  Liebherr GmbH, DE 
Freezer -80 °C, Heraeus  Thermo-Fisher Scientific, USA 
Heat plate  Thermo Flächenheizungs GmbH, DE 
Hemocytometer Neubauer chamber   Paul Marienfeld GmbH, USA 
Laminar Air Flow Class II Safety Cabinet Clean Air Systems, DE 
Mastercycler gradient   Eppendorf AG, DE 
Microcentrifuge Heraeus Pico 17 ThermoFisher Scientific, USA 
Microscope PrimoVert   Carl Zeiss Microscopy GmbH, DE 
Nanodrop Synergy HT Bio-Tek, Inc., USA 
Pipetboy 2  Integra Bioscience 
Pipettes P2, P10, P20, P200, P1000  Gilson Inc., USA 
QIAgility Robotic workstation for PCR setup  Qiagen GmbH, DE 
Real-time PCR cycler Rotor–GeneQ    Qiagen GmbH, DE 
Refrigerator 4 °C, Comfort  Liebherr GmbH, DE 
Shaver Exacta Aesculap, DE 
Sterile cell culture hood, HERAsafe Thermo Fisher Scientific, USA 
Sterile tweezer and scissors  Aesculap AG, DE 
Timer  Carl Roth GmbH, DE 
Tissue Lyser Lt   Qiagen GmbH, DE 
Tomy-Capsulefuge PMC-060   BioSurplus, USA 
Vortex mixer   neoLab, DE 
 
3.1.02 Software 
Table 3. Software used for experimental analysis 
Function Software Company 
 
Statistical analysis 
GraphPad Prism 6.0 GraphPad Software, USA 
Microsoft Excel 2010 Microsoft Corporation, USA 
RNA measurement Gen5 2.00 Ink BioTek Instruments, USA 
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q-PCR analysis 
Rotor-Gene 6 Version 6.1 Qiagen GmbH, DE 
Rotor-Gene Q Version 2.3.1 Qiagen GmbH, DE 
 
3.1.03 Websites 
Table 4. Websites used for experimental procedures 
Internet address Program Function Provider 
 
https://ncbi.nlm.nih.gov 
PubMed Literature 
research National Center for 
Biotechnology 
Information Primer-Blast 
Primer 
design 
https://pga.mgh.harvard.edu/primerbank/ Primer Bank MGH-PGA 
Primer 
design 
The Massachusetts 
General Hospital 
 
3.1.04 Consumables 
Table 5. Consumables used for experimental procedures 
Consumables Company 
 
Aluminum foil  IGEFA GmbH, DE 
Cell culture dish (100 mm) Greiner bio-one AG, DE 
Cell culture flasks T-75  Greiner bio-one AG, DE 
Cell culture plates (6 and 24 well)  Greiner bio-one AG, DE 
Cell scraper 28 cm length Greiner bio-one AG, DE 
Cellstarâ serological pipette (5 mL/10 mL/25 mL) Greiner bio-one AG, DE 
Conducting filter tips (50 µL/200 µL)  Qiagen GmbH, DE 
Cover glass 24 x 40 mm Gerhard Menzel GmbH, DE 
Disposable scalpel  Aesculap AG, DE 
Erlenmeyer flask (25 mL) LabSolute, DE 
Falcon cell strainer (70 µm)  Greiner bio-one AG, DE 
FalconÔ tubes (15 mL/50 mL) Greiner bio-one AG, DE 
PCR 0.1 mL 4-tube and 4-cap strips Biozym Biotech GmbH, DE 
Peha-soft® nitrile powder free gloves Paul Hartmann AG, DE 
Pipet tips (1µL-1000 µL) Greiner bio-one AG, DE 
QIAshredder Spin Columns Qiagen GmbH, DE 
Reaction tubes (0.5 mL)    Sarstedt AG, DE 
Reaction tubes (1.5 mL/2 mL)    Greiner bio-one AG, DE 
Single–use insulin syringe U-100 (1 mL)   B. Braun AG, DE 
Stainless steel beads 5-mm Qiagen GmbH, DE 
Standard biopsy punch 6-mm Pfm medical AG, DE 
Wooden tongue depressor  Heinz Herenz GmbH, DE 
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3.1.05 Media and Buffers 
Table 6. Media and buffers used for experimental procedures 
Media and buffers Composition / Company 
 
Complete fibroblast media DMEM, 10% FCS, 1% Pen/Strep 
Complete macrophages media  DMEM, 10% FCS, 1% ZellShieldÒ 
Complete FAD media 
(keratinocytes) 
DMEM/Ham’s F12, low Calcium, 50 mL FCS (Chelex-
treated), 5 mL Glutamax [100x], 5 mL Pyruvate [100x], 2,5 
mL Pen/Strep, 2 mL Adenin [250x], 500 µl EGF [1000x], 
500 µl Insulin [1000x], 250 µl Hydroxycortison [2000x], 50 
µl Choleratoxin [10-5M]  
Dulbecco′s Modified Eagle′s 
Medium (DMEM)   Biochrom AG, Berlin DE 
Phosphate buffered saline 
(PBS)  Dulbecco w/o Ca
2+, w/o Mg2 , Biochrom AG, Berlin DE 
Freezing media Complete media with 10% DMSO 
RNA lysis buffer RLT buffer, 10% ß-Mercaptoethanol  
Tissue lysis solution LBA, 1-Thioglycerol (TG) 
 
3.1.06 Reagents  
Table 7. Reagents used for experimental procedures 
Reagent Company 
 
Adenin Sigma-Aldrich Corporation, USA   
Chelex PAA Laboratories, USA 
Choleratoxin Sigma-Aldrich Corporation, USA   
DMSO Sigma-Aldrich Corporation, USA   
Dry ice  Sigma-Aldrich Corporation, USA   
EGF Invitrogen AG, USA 
Ethanol absolute VWR International S.A.S, France 
Fetal Calf Serum (FCS)  Biochrom AG, Berlin DE 
Glutamax Invitrogen AG, USA 
Go TagÒ qPCR Master Mix, 2X  Promega, USA 
Hydroxycortison Sigma-Aldrich Corporation, USA   
Insulin Sigma-Aldrich Corporation, USA   
Isopropanol 70% Dr. Schumacher GmbH, DE 
Liberase DL Research Grade  Roche Diagnostics  
Lipopolysaccharides (LPS) E.coli 026:B6  Sigma-Aldrich Corporation, USA   
Nuclease-Free Water  Promega, USA 
Penicillin/Streptomycin 10.000 U/mL / 10.000 µg/mL  Biochrom AG, DE 
Pyruvate PAA Laboratories, USA 
PureCol® collagen Type I  3 mg/mL  (bovine hide) Sigma-Aldrich Corporation, USA   
qScript cDNA SuperMix Quanta BioSciences, USA 
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RLT Lysis buffer  Qiagen GmbH, DE 
ß-Mercaptoethanol  Sigma-Aldrich Corporation, USA   
Trypsin/EDTA Solution 0.05%/0.02% (w/v) in PBS w/o 
Ca2+, w/o Mg2+   
Biochrom AG, DE 
 
Trypsin 0,25% (w/v) in PBS w/o Ca2+, w/o Mg2+  Biochrom AG, DE 
Trypan Blue 0.4% solution  Sigma-Aldrich Corporation, USA   
ZellShield® Minerva Biolabs GmbH, DE 
 
3.1.07 Stimulation reagents 
Table 8. Stimulation reagents used for generating cultures of fibroblast, RAW264.7 macrophages and 
immortalized keratinocytes 
Cytokine Company 
 
Recombinant mouse Interleukin 1ß (IL-1ß) Miltenyi Biotec, DE 
Recombinant mouse Tumor Necrosis Factor α (TNFα) Miltenyi Biotec, DE 
Recombinant mouse Interleukin 4 (IL-4) Miltenyi Biotec, DE  
Recombinant mouse Transforming Growth Factor ß (TGFß) Miltenyi Biotec, DE 
Recombinant mouse Interferon γ (IFN-γ) Miltenyi Biotec, DE 
Lipopolysaccharides (LPS)  Sigma-Aldrich, USA 
 
3.1.08 Anesthesia and analgesia used for the full-thickness skin wound model 
Table 9. Anesthesia and analgesia used for skin wounding in mice 
Component Company 
 
Tramadolhydrochlorid 50 mg/1 mL  Grünenthal GmbH, DE  
Ketaminhydroclorid 10% (Ketamin) WDT e.G., DE 
Rompun 2% (Xylazin)  Bayer Vital GmbH, DE 
NaCl 0.9%  B. Braun AG, DE 
Eye ointment, 5% Dexpanthenol Bayer Vital GmbH, DE 
Octenisept solution Schülke & Mayr GmbH, DE 
 
3.1.09 Kits 
Table 10. Kits used according to manufacturer’s instructions. 
Kit Company 
 
Relia Prepä RNA Tissue Miniprep System    Promega, USA 
Rneasyâ Mini Kit Qiagen GmbH, DE 
PCR Mycoplasma Test Kit PanReac AppliChem, DE 
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3.1.10 Quantitative reverse-transcription PCR primers 
Table 11. Primer name, accession number, primer sequence, amplicon length and annealing temperature of 
each gene used in the present study. 
Primer 
name 
Accession 
Nr. Primer sequence (5’– 3’) 
Amplico
n length 
(bp) 
Annealin
g temp. 
(°C) 
Col-Ia1 NM007742.4 
F: TGT GCC ACT CTG ACT GGA AG 
R: TTC TTT TCC TTG GGG TTC G 
160 58 
Arg1 NM007482.3 F: AAC ACT CCC CTG ACA ACC AG  
R: TCC CCA GGG TCT ACG TCT C 
170 61 
IL-10 NM010548.2 
F: AGC CGG GAA GAC AAT AAC TG  
R: CAT TTC CGA TAA GGC TTG G 
188 61 
IL-1ß NM_008361.4 
F: GAC AAC TGC ACT ACA GGC TCC  
R: AGG CCA CAG GTA TTT TGT CG 
168 60 
iNOS NM_010927.4 F: GTG GCC GTG GTC ACC TAC  
R: CCC AAT GAG GAT GCA AGG 
171 62 
Keratin 
14 NM001313956.1 
F: GGG CTC TTG TGG TAT CGG  
R: TAA CCG ACA TGC CCC CCG TAG 
97 61 
Lef-1 NM_010703.4 
F: GCA CGG AAA GAG AGA CAG CTA  
R: TCT GGG ACC TGT ACC TGA AGT 
130 60 
Relm-α NM020509.3 F: CCC TCC ACT GTA ACG AAG AC  
R: CAA CGA GTA AGC ACA GGC AG 
166 61 
Rplp0 NM007475.5 F: GGA CCC GAG AAG ACC TCC TT  
R: GCA CAT CAC TCA GAA TTT CAA TGG 
85 62 
TGFß NM011577.2 
F: CTT CAA TAC GTC AGA CAT TCG  
R: GTC AAA AGA CAG CCA CTC AG 
196 58 
TNF-a NM001278601.1 
F: CTT AGA CTT TGC GGA GTC CG  
R: ACA GTC CAG GTC ACT GTC CC  
254 62 
Wnt-2a NM_023653.5 F: CCT GTG ATC CAA AGA AGA AAG G  
R: CCT TCC TTC CAG CTC TGT TG 
163 61 
Wnt-3a NM009522.2 
F: GTG CGA CCT GTT GTG CTG  
R: CCA GAC AGG AGC TTC TCC C 
364 61 
Wnt-5a NM_009524.3 
F: ACA TTG GAG AAG GTG CGA AG  
R: GTC TCT CGG CTG CCT ATT TG 
130 61 
Wnt-5b NM_009525.3 F: AAG GAG TTT GTG GAT GCC C  
R: TCT TGA GGC TGC AGG ACC 
171 58 
Wnt-7a NM009527.3 F: TGT GAC CTC ATG TGC TGT GG  
R: TCT GAC CTG TGA CCG CAT TC 
159 62 
Wnt-10a NM009518.2 
F: GCT CAA CGC CAA CAC AGT G  
R: CGA AAA CCT CGG CTG AAG ATG 
221 60 
Wnt-10b NM011718.2 
F: TCT CTTT CAG CCC TTT GCT CGG AT  
R: ACA ACT GAA CGG AAG GAG AAG CCT 
514 61 
Wnt-11 NM_001285792.1 F: TGC TGC TAC GTC ACC TGC  
R: AGT GGA GGC ACA GCA CAA G 
192 62 
Wnt-16 NM_053116.4 
F: GGA GCT GTG CAA GAG GAA AC  
R: AGT GGC GAC CAT ACA GTT CC 
118 62 
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3.2 EXPERIMENTAL PROCEDURES 
3.2.01 Mice 
8-11 weeks old (male and female) wild type (WT) C57BL/6J mice were purchased from the 
Medical Experimental Center of the University of Leipzig, Germany. All mice were kept under 
specific free pathogen conditions. The mice had standard rodent diet and water. The light cycle 
was set to 12 h. Animal care and experiments were performed in accordance to the institutional 
guidelines of German Federal Law and local authorities of Sachsen. Procedures were approved by 
the Ethics Commission of the Medical Faculty of the University of Leipzig (Proposal TVV24-12). 
 
3.2.02  Cell Lines 
The H133WT immortalized keratinocytes cell line and the complete FAD media (see Table 6) 
were kindly provided by Prof. T. Magin from the Institute of Biology of the University of 
Leipzig. The cells were cultured in complete FAD media (0.05 mM CaCl2). 
 
The RAW264.7 cell line [74] was kindly provided by Dr. Axel Schoeniger from the Institute of 
Physiological Chemistry of the University of Leipzig. The cells were cultured in complete 
macrophages media (see Table 6). All macrophages procedures were performed in a biosafety 
level 2 laboratory. 
 
3.2.03 Cell counting with trypan blue stain and hemocytometer method  
Trypan blue staining and the hemocytometer method was used to determine the total number of 
viable cells obtained from cell cultures. Previous to cell counting, trypan blue (0.4%) was added 
to the cell suspension in a 1:2 radio and then mixed thoroughly. The trypan blue-cell suspension 
was transferred to the hemocytometer chamber and placed on the microscope. Blue stained cells 
were excluded from the count, as they were considered not viable. The following formula was 
used to calculate the total number of viable cells: 
 
 
 
 
Total of viable cells/mL  =  Total cells counted   x   
dilution	factor
number	of	squares   x   10,000 cells/mL 
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3.2.04 Preparation of murine H133WT immortalized primary keratinocytes cultures 
The immortalized wild-type mouse H133WT keratinocytes were cultured in complete FAD media 
(0.05 mM CaCl2) on collagen I-coated T-75 flasks (PureColÒ 3 mg/mL) at a density of 15,000 
cells/cm2. Upon a cell confluence of ~80% was reached, cells were split 1:2 and left to confluence 
again. At the second passage cells were spun for 5 min at 1000 rpm at RT. The supernatant was 
then discarded and the pellet was resuspended in 5 mL of complete FAD media. Cell counting 
was performed by using Trypan Blue Stain and the Hemocytometer Method (see Section 3.2.03). 
Cells were seeded in a 24-well plate at a density of 100,000 cells/well and incubated for 24 hours 
before stimulation was conducted. 
 
3.2.05 Preparation of RAW264.7 murine macrophages cultures 
RAW264.7 macrophages were thawed into 10 mL of complete media (DMEM supplemented with 
10% FCS and 1% ZellShieldâ). To free the cells of DMSO, the mixture was spun for 7 min at 
270 g at RT. The pellet was then resuspended in 1 mL of complete media and dispensed into a T-
75 culture flask containing 10 mL of complete media and left for incubation at 37 °C with 5% 
CO2 until cells reached ~80% confluency. Mycoplasma contamination was ruled out using the 
PCR Mycoplasma Test Kit (AppliChem) according to manufacturer’s instructions. After that, 
macrophages were split 1:3 and left to confluence once again inside the cell culture incubator. 
Once an ~80% level of confluency was reached, media was discarded and macrophages were 
scraped from the bottom surface of the flask and placed in a 50 mL falcon tube with 10 mL 
complete DMEM media. Cell counting was performed by using the Trypan Blue Stain and the 
Hemocytometer Method (see Section 3.2.03). Afterwards, cells were centrifuged and the pellet 
was resuspended in a 300,000 cells/mL suspension. RAW264.7 macrophages were seeded in a 
24-well plate at a density of 150,000 cells/well and incubated for 24 hours before type 1 and type 
2 immunity stimulation was conducted (see Section 3.2.07). Additionally, RAW264.7 
macrophages were stimulated with recombinant murine INF-γ (10 ng/mL) plus LPS (100 ng/mL) 
or IL-4 (40 ng/mL) in complete DMEM media to induce M1 and M2 macrophage differentiation 
respectively. 
 
3.2.06 Preparation of primary murine fibroblasts cultures 
For this procedure mice were sacrificed with CO2 inhalation and cervical dislocation. Then, the 
back of the mice was shaved and the skin disinfected. Fibroblasts were isolated from the skin with 
Liberase DL at a concentration of 0.035 mg/mL diluted in FCS free fibroblast media (DMEM 
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supplemented with 1% antibiotics). The mixture was stirred for 1.5 hours at 37 °C with 5.0% 
CO2. To block the enzymatic reaction, 10 mL of complete fibroblasts media was added to the 
mixture and then all was filtered through a 70 µm strainer over a 50 mL falcon and spun for 7 min 
at 1000 rpm at RT. The supernatant was then discarded and the pellet was resuspended in 20 mL 
of complete fibroblast media and split into two 100-mm cell culture dishes in a ratio of 1:2 and 
incubated at 37 °C with 5% CO2 till the cells reached a confluence level of ~80%. Cell detaching 
was performed using 5 mL of 0.05% Trypsin/EDTA with an incubation time of 7 min at 37 °C 
with 5.0% CO2. Thereafter, the reaction was neutralized with 10 mL of complete fibroblast media 
and cells were spun down for 7 min at 1000 rpm at RT. Cell number determination was 
performed using the Trypan Blue Stain and the Hemocytometer Method (see Section 3.2.03). 
Cells were resuspended at a density of 200,000 cells/mL. Finally, fibroblasts were seeded in a 24-
well plate (20,000 cells/well) and incubated for 24 hours before type 1 and type 2 immunity 
stimulation was conducted (see Section 3.2.07). 
 
3.2.07 Type 1 and type 2 immunity cell stimulation 
For stimulation 150,000 RAW264.7 macrophages, 100,000 H133WT keratinocytes and 20,000 
primary fibroblasts were seeded into a 24-well plate. After 24 hours, in order to resemble type 1 
immunity, cells were stimulated with recombinant mouse TNF-α (10 ng/mL) and IL-1ß (10 
ng/mL) in complete cell culture media. To resemble type 2 immunity, cells were stimulated with 
either TGFß (10 ng/mL) or IL-4 (10 ng/mL) and in combination to pinpoint their specific 
regulatory effects on the canonical Wnt/ß-catenin signaling activation. Controls were left 
unstimulated. Cells were cultured for three different time points (24 h, 48 h and 72 h). 
Supernatant was harvested, centrifuged to remove cells and transferred into a 1.5 mL tube to be 
stored at -80 °C. For RNA isolation, cells were lysed by adding ß-mercaptoethanol (ß-ME) and 
RLT buffer (1:100). Cell detachment was controlled by microscopy and RNA isolation was 
performed according to protocol (see Section 3.2.08). Experiments were performed as triplicates. 
 
3.2.08 Cell RNA isolation 
Total RNA was extracted from the cultivated cells using RNeasyâ Mini Kit from Qiagen 
according to manufacturer’s instructions. Total RNA was eluted with 25 µL RNase-free water. 
The RNA concentration and quality were measured with Nanodrop Synergy HT and stored at -80 
°C for cDNA synthesis. 
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3.2.09 Mice wounding  
Mice were anesthetized by i.p. injection of ketamine/xylazine (ketamin100 mg/kg, xylazine 10 
mg/kg) diluted with sterile 0.9% NaCl. After assessing anesthesia level, the back was shaved and 
the skin was thoroughly disinfected. Eye ointment was applied to prevent ulcers during 
anesthesia. Then the dorsal skin was folded at the midline (spinal cord was used as anatomical 
reference) and two 6-mm diameter full-thickness excisional wound (epidermis, dermis and 
subcutaneous tissue) were generated with a biopsy punch (Figure 6) [75]. Normal body 
temperature was maintained during anesthesia through an electric heating pad. For the anesthesia 
recovery, mice were placed individually in a warm, dry and quiet environment. Postoperative 
analgesia was performed with tramadolhydrochloride diluted in drinking water at a concentration 
of 0.16 mg/mL. Several post-wound time points were collected for the analysis of the early and 
late inflammation phase of the wound healing. The wounded skin was then compared to 
unwounded skin biopsies. The mice wounding procedures were performed by authorized and 
certificated personnel in the Medical-Experimental Center of the Medical Faculty of Leipzig 
(MEZ). 
 
 
Figure 6. Full-thickness excisional wound model. 6-mm diameter skin biopsies (epidermis, dermis and 
hypodermis) created on the dorsum of the mouse. (Adapted from [76]). 
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3.2.10 Whole skin tissue isolation  
For this procedure mice were sacrificed with CO2 inhalation and cervical dislocation. Then, the 
wound edges were excised (2-3 mm wound edge) and placed in a petri dish with 1 mL PBS. The 
subcutaneous layer was mechanically removed from the wounded dermis with the use of a 
scalpel. The procedure was repeated for every post-wound day and unwounded controls. 
Following, the RNA of the tissue was isolated (see Section 3.2.12). 
 
3.2.11 Epidermal and dermal tissue isolation  
For this procedure mice were sacrificed with CO2 inhalation and cervical dislocation. Then, 
2-3 mm wound edges were placed in a petri dish with 1 mL PBS. The subcutaneous layer was 
removed from the wounded dermis mechanically with the use of a scalpel. Following, the 
epidermis was separated from the dermis through an enzymatic digestion by submerging the 
tissue into 2 mL of 0.25% trypsin for 24 hours at 4°C. The next day the epidermis was smoothly 
peeled away from the dermis with a scalpel and then both skin tissue layers were cut into pieces. 
The procedure was repeated for every post-wound day and unwounded controls. Following, the 
RNA of the tissue was isolated (see Section 3.2.12). 
 
3.2.12 Tissue RNA isolation 
To extract the total RNA from the epidermal and dermal fractions and from the whole skin of the 
mice, the tissues were disrupted for 5 min at 50 Hz in a tissue homogenizer with tissue lysis 
solution and two 5-mm stainless steel beads. Following, the homogenate was transferred into a 
1.5 mL tube. The ReliaPrepä RNA Tissue Miniprep Systems protocol for fibrous tissue was 
followed in accordance to manufacture’s instruction. The total RNA was eluted by adding 17 µl 
of RNase-free water. RNA samples were stored at –80 °C for cDNA synthesis. 
 
3.2.13 cDNA synthesis 
cDNA was synthetized using qScript cDNA SuperMix. All contents were combined in a 0.5 mL 
tube sitting on ice for a total of 20 µL volume reaction. Then the reaction was incubated in the 
Masterclycler Gradient for 5 min at 25 °C, 30 min at 42 °C, 5 min at 85 °C and hold at 4 °C. The 
generated cDNA from the in vitro experiments was diluted 1:4 for q-PCR amplification. The 
cDNA from the in vivo experiments was not diluted. cDNA was stored at -20 °C. 
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Table 12. Components used for cDNA synthesis 
Component Volume for 20 µL rxn 
 
qScript cDNA SuperMix (5X) 4 µL 
RNA template variable (see Table 13) 
RNase/DNase-free water variable 
 
Table 13. RNA template used for cDNA synthesis 
RNA template (ng/µL) Samples 
 
300 ng/µL Samples in vivo 
300 ng/µL Primary fibroblasts 
500 ng/µL RAW264.7 macrophages 
500 ng/µL Immortalized keratinocytes 
 
3.2.14 Quantitative Real-Time PCR (qPCR) 
q-PCR was performed using Go TagÒ qPCR Master Mix. See Table 11 for list of primers used for 
q-PCR analysis. Specificity of PCR amplification was validated by the generation of a melting 
curve. Data were reported in absolute gene expression presented as copy number per sample 
(arbitrary units) and relative gene expression (2-DDCt method). RPLP0 was used as reference gene 
for normalization.  
 
Table 14. Reagents for the amplification of the cDNA fragments  
In µL Reagent 
 
 10 µL Go TagÒ qPCR Master Mix, 2X 
   7 µL Nuclease free H2O 
0.5 µL Forward primer 
0.5 µL Reverse primer 
   2 µL cDNA 
 
3.2.15 Statistical analysis 
Data are presented as mean ± standard deviation from at least three independent experiments as 
indicated in the figure legends. Statistical significance was determined using the Students t-test 
(corrected for multiple comparisons using the Holm-Sidak method) and Grubbs’ test for outliers. 
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All p values < 0.05 are considered to be significant. Statistical analysis was performed using 
GraphPad Prism and Excel 2010. 
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4 EXPERIMENTAL RESULTS 
4.1 Canonical Wnt/ß-catenin signaling activity in different skin cell populations under 
type 1 and type 2 immunity cytokines stimulation in vitro 
Wnt activity is known to be required during wound healing to activate morphogenic events for the 
tissue restoration and regeneration [40]. Currently, most of the data on Wnt activity during wound 
healing focuses on epidermal cells [39] and the dermis as a whole [51]. Information about in 
which specific cell populations of the dermis and at which time points the canonical 
Wnt/ß-catenin is activated is still incomplete. Moreover, a relationship between immunity (type 1 
vs. type 2) and Wnt-activity has not been yet established. 
 
To gain a first insight, we explored the activation of the canonical Wnt/ß-catenin signaling in 
three relevant cells (keratinocytes, fibroblasts and macrophages), which participate in the wound 
healing process [77], under type 1 and type 2 immunity conditions. First, we cultivated primary 
fibroblasts, immortalized keratinocytes and macrophages cell line RAW264.7 from mice. Then, 
we stimulated each cell population with type 1 (TNF-a and IL-1ß) and type 2 (IL-4 and TGFß) 
immunity cytokines and analyzed the expression of Lef-1, a target gene of the canonical 
Wnt/ß-catenin activation, at three different time points. We found that Lef-1 was upregulated in 
keratinocytes and fibroblasts only under type 2 immunity cytokine stimulation (Figure 7a). 
Furthermore, Lef-1 was found downregulated in RAW264.7 macrophages after 72 hours of type 1 
immunity cytokine stimulation (Figure 7a). 
 
It is known that TGFß which belongs to type 2 immunity response, stimulates the activation of the 
canonical Wnt/ß-catenin signaling [49]. However, it is not known if any other type 2 cytokine can 
also independently activate the canonical Wnt/ß-catenin signaling. We addressed this question by 
stimulating murine keratinocytes and fibroblasts either with IL-4 or TGFß for 24, 48 and 72 
hours. Then we analyzed both cell populations for Lef-1 expression. Our results in keratinocytes 
and fibroblasts showed that only TGFß upregulated the canonical Wnt/ß-catenin signaling. 
Moreover, a synergistic effect between TGFß and IL-4 was not found (Figure 7b). 
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Figure 7. Effect of type 1 and type 2 immunity cytokines on canonical Wnt/ß-catenin signaling 
activity in vitro. a) Gene expression analysis of Lef-1 in murine immortalized keratinocytes, primary 
fibroblasts and RAW264.7 macrophages after stimulation with type 1 immunity cytokines: TNFα and IL-1ß 
(both at 10 ng/mL) and type 2 immunity cytokines: IL-4 and TGFß (both at 10 ng/mL) for 24 h, 48 h and 72 
hours. Controls were left unstimulated. b) Gene expression analysis of Lef-1 in immortalized keratinocytes 
and primary fibroblasts stimulated with TGFß (10 ng/mL) and IL-4 (10 ng/mL) separately and in 
combination for 24 h, 48 h and 72 hours. Controls were left unstimulated. Gene expression is normalized to 
reference gene Rplp0 and presented as arbitrary units (AU). Data are expressed as mean ± standard 
deviation, n = at least 3 independent experiments. Statistical significance was determined by unpaired two-
tailed Student’s t-test *p ≤ 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001. 
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Macrophages are main drivers of type 1 and type 2 immunity responses in the skin during wound 
healing by polarizing into M1 and M2 phenotypes [78]. To test whether this polarization activates 
the canonical Wnt/ß-catenin signaling, we induced M1-polarization using INFg and LPS and 
M2-polarization using IL-4, as previously described [79]. The differentiation into M1 and M2 
phenotype was verified through the mRNA expression of iNOS and Arginase 1, respectively 
(Figure 8a). Similar to our first experiments on macrophages, M1 and M2 polarized RAW264.7 
macrophages did not show a significant change in Lef-1 expression (Figure 8b). Our results 
suggest that the canonical Wnt/ß-catenin signaling is not activated in macrophages. 
 
 
Figure 8. Effect of M1 and M2 polarization on canonical Wnt/ß-catenin signaling activation in vitro. 
a) Gene expression analysis of M1 and M2 phenotype markers in RAW264.7 macrophages after induced 
polarization with INFg (10 ng/mL) + LPS (100 ng/mL) and IL-4 (40 ng/mL) respectively for 24 h, 48 h and 
72 hours. Controls were left unstimulated. b) Gene expression analysis of Lef-1 in polarized M1 and M2 
RAW264.7 macrophages. Controls were non-stimulated RAW264.7 macrophages. Gene expression is 
normalized to reference gene Rplp0 and presented as arbitrary units (AU). Data are expressed as mean ± 
standard deviation, n = 4 independent experiments. Statistical significance was determined by unpaired 
two-tailed Student’s t-test *p ≤ 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001. 
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4.2 Canonical Wnt/ß-catenin signaling activity under type 1 and type 2 immunity 
conditions during wound healing in vivo 
In vitro we demonstrated that type 2 immunity cytokines activate the canonical Wnt/ß-catenin 
signaling in keratinocytes and fibroblasts. Then, we aimed to confirm this result in vivo. 
Therefore, we first defined the time points in which type 1 (IL-1ß and TNFa) and type 2 (Relm-a 
and IL-10) markers were expressed during wound healing. For this, we performed a wound 
healing study in mice and analyzed the wound tissue in a tight kinetic at days 1, 3, 5, 7, 8, 10, 12 
and 14 post wounding (PWD). Here, we confirmed that IL-1ß and TNFa were upregulated during 
the early inflammatory phase, as shown by others [80][13], having the peak of expression at post 
wound day 1 (PWD1). Also as reported by others [78], type 2 cytokines were expressed in the late 
inflammatory phase, with Relm-a and IL-10 reaching their peak of expression at PWD12 (Figure 
9). 
 
Figure 9. Kinetic of type 1 and type 2 immunity cytokines expression in wounded whole mice skin. 
Gene expression analysis of type 1 immunity markers IL-1ß and TNF-α and type 2 immunity markers 
Relm-α and IL-10 along wound healing in whole murine skin. Gene expression is normalized to reference 
gene Rplp0 and presented as arbitrary units (AU). n = 4 independent experiments. Data are expressed as 
mean value.  
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Through the upregulation of specific cytokines, we showed that type 1 immunity is predominant 
between PWD1 and PWD3, whereas type 2 immunity is present at PWD12 and PWD14. Taking 
out these crucial time points we next aimed to examine the canonical Wnt/ß-catenin signaling 
activation in vivo. For this, we decided to explore the epidermal and dermal fractions of wounded 
skin, since it is known that they are mainly composed of keratinocytes and fibroblasts respectively 
[77]. The epidermal and dermal fraction separation was performed using a mild enzymatic 
treatment, in order not to affect the quality of the obtained RNA. Although the separated fractions 
might have contained other cells, such as melanocytes, endothelial cells, macrophages and other 
immune cells [77], our separation approach allowed us to gain a first insight into the activation of 
the epidermal and dermal canonical Wnt/ß-catenin signaling in vivo under type 1 and type 2 
immunity conditions. 
 
To test the quality of our separation method and the purity of the epidermal and dermal fractions, 
we measured the expression of Keratin 14 (epidermal marker) and Collagen I-a1 (dermal marker) 
in both skin fractions. We found that Keratin 14 was mainly expressed at significant levels in the 
epidermal fraction at all time points, while Collagen I-a1 was significantly expressed in the 
dermal fraction compared to the reduced expression in the epidermal fraction (Figure 10). 
 
 
Figure 10. Purity of epidermal and dermal fractions after tissue separation. Collagen I-α1 and Keratin 
14 expression in wounded epidermal and dermal tissue fractions. Gene expression is normalized to 
reference gene Rplp0. Keratin 14 is shown as fold change (2^-ΔΔCt) relative to controls of unwounded 
epidermis and Collagen I-α1 relative to unwounded dermis, n = at least 3 independent experiments for each 
time point. Data are expressed as mean ± standard deviation. Statistical significance was determined by 
unpaired two-tailed Student’s t-test *p ≤ 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001. 
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PWD12 and reaching a maximum at PWD14. Our data from the dermal fraction experiments did 
not show a statistically significant increase of Lef-1 but suggests that its expression is reduced 
early upon wounding and then upregulated at PWD14 (Figure 11). We speculate that the result 
from the dermal fraction is biased by the presence of other non-fibroblast different cell 
populations that reside within the dermis (e.g., macrophages, peripheral nervous system, 
endothelial and immune system cells) with low or no expression of Lef-1 [77]. 
 
 
Figure 11. Canonical Wnt/ß-catenin activity in epidermal and dermal fractions of wounds. q-PCR 
analysis of Lef-1 expression in wound epidermal and dermal tissue fractions at the early (PWD1 and 
PWD3) and late inflammatory phase (PWD12 and PWD14) during wound healing. Gene expression is 
normalized to reference gene Rplp0 and presented as arbitrary units (AU). n = at least 4 independent 
experiments for each time point. Data are expressed as mean value. Statistical significance was determined 
by unpaired two-tailed Student’s t-test *p ≤ 0.05, ** p < 0.01. Grubbs test was used to identify outliers in 
the epidermis at PWD12 where there was a significant (p <0.05) considerable dispersion of the data. 
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keratinocytes and primary fibroblasts using the same cytokine combinations from the experiments 
before. 
 
In vitro we found that Wnt-ligands were upregulated in keratinocytes (Wnt-2a, Wnt-3a, Wnt-5a, 
Wnt-5b, Wnt-7a, Wnt-10a, Wnt-10b, Wnt-11 and Wnt-16) (Figure 12a) and in fibroblasts (Wnt-2a, 
Wnt-5a, Wnt-10b and Wnt-11) (Figure 12b) both cell populations in which Lef-1 was shown to be 
upregulated. Wnt-5a and Wnt-11 were particularly strongly upregulated in keratinocytes under 
type 2 immunity conditions compared to controls. Wnt-5a was found to be upregulated in 
keratinocytes also under type 1 immunity conditions, even though Lef-1 was not upregulated 
under these immunity conditions. In contrast, in RAW264.7 macrophages we found no 
Wnt-ligand upregulation neither under type 1 nor type 2 conditions (Figure 12c). Furthermore, 
their Wnt-ligands expression was downregulated under type 1 immunity (Wnt-2a, Wnt-3a, 
Wnt-7a, Wn-10a and Wnt-10b) and under type 2 immunity (Wnt-5b, Wnt-7a and Wnt-10a). Tables 
15 and 16 provide an overview of the effect of type 1 and type 2 immunity cytokines on the 
expression of different Wnt-ligands in immortalized keratinocytes, primary fibroblasts and 
RAW264.7 macrophages. 
 
Table 15. Effect of type 1 immunity on Wnt-ligands gene expression in vitro. q-PCR analysis of 
Wnt-ligands expression in murine immortalized keratinocytes, primary fibroblasts and RAW264.7 
macrophages. Murine cells were stimulated with a combination of cytokines: IL-1ß and TNFα (both at 10 
ng/mL) which simulated the early inflammatory phase of the wound healing. 
Wnt 
ligand 
Keratinocytes Fibroblasts RAW264.7 macrophages 
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 
p-value p-value p-value p-value p-value p-value p-value p-value p-value 
Wnt-2a - - - - - - - - < 0.05 ¯ 
Wnt-3a - - - - - - - - < 0.05 ¯ 
Wnt-5a < 0.0001 ¯ < 0.05    ¯ < 0.05   ↑ - - - - - - 
Wnt- 5b - - - - - - - - - 
Wnt-7a - - - - - - - - - 
Wnt-10a - - - - - - < 0.05 ¯ - - 
Wnt-10b - - - - - - < 0.05 ¯ < 0.01 ¯ - 
Wnt-11 - - - - - - - - - 
Wnt-16 - - - - - - - - - 
Gene expression is normalized to reference gene Rplp0 and presented as fold change relative to unstimulated controls. 
Statistical significance was determined by unpaired two-tailed Student’s t-test. ↑ = gene upregulation, ¯ = gene 
downregulation. 
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Table 16. Effect of type 2 immunity on Wnt-ligands gene expression in vitro. q-PCR analysis of 
Wnt-ligands expression in murine immortalized keratinocytes, primary fibroblasts and RAW264.7 
macrophages. Murine cells were stimulated with a combination of cytokines: IL-4 and TGFß (both at 10 
ng/mL) which simulated the late inflammatory phase of the wound healing. 
Wnt ligand  
Keratinocytes Fibroblasts RAW264.7 macrophages 
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 
p-value p-value p-value p-value p-value p-value p-value p-value p-value 
Wnt-2a - < 0.01    ↑ < 0.0001↑ < 0.05 ↑ - < 0.01 ↑ - - - 
Wnt-3a - < 0.05    ↑ - - - - - - - 
Wnt-5a < 0.0001 ↑ < 0.001  ↑ < 0.0001↑ < 0.05 ↑ - - - - - 
Wnt- 5b < 0.05     ¯ < 0.05    ↑ < 0.01    ↑ - - - - < 0.05 ¯ - 
Wnt-7a - < 0.01    ↑ - - - - < 0.05 ¯ < 0.01 ¯ - 
Wnt-10a < 0.001   ↑ - - - - - < 0.05 ¯ < 0.05 ¯ - 
Wnt-10b - < 0.05     ↑ < 0.01    ↑ - < 0.05 ↑ < 0.05 ↑ < 0.05 ¯ < 0.01 ¯ - 
Wnt-11 < 0.0001 ↑ < 0.0001 ↑ < 0.0001↑ < 0.05 ↑ < 0.01 ↑ < 0.01 ↑ < 0.05 ¯ - - 
Wnt-16 - < 0.05    ↑ < 0.001  ↑ - - - < 0.01 ¯ - - 
Gene expression is normalized to reference gene Rplp0 and presented as fold change relative to unstimulated controls. 
Statistical significance was determined by unpaired two-tailed Student’s t-test. ↑ = gene upregulation, ¯ = gene 
downregulation. 
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Figure 12. Effect of type 1 and type 2 immunity on Wnt-ligands expression in a) immortalized 
keratinocytes, b) primary fibroblasts and c) RAW264.7 macrophages. Gene expression analysis of 
several Wnt-ligands after stimulation with type 1 (IL-1ß 10 ng/mL + TNFα 10 ng/mL) and type 2 (IL-4 10 
ng/mL + TGFß 10 ng/mL) immunity cytokines for 24 h, 48 h and 72 hours. Controls were left 
unstimulated. Gene expression is normalized to reference gene Rplp0 and expressed as arbitrary units (AU) 
n = at least 3 independent experiments for each time point. Data are expressed as mean ± standard 
deviation. Statistical significance was determined by unpaired two-tailed Student’s t-test *p ≤ 0.05, ** p < 
0.01, *** p <0.001, **** p < 0.0001. 
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Furthermore, when we analyzed the Wnt-ligand expression in polarized M1 and M2 macrophages 
we found that Wnt-2a, Wnt-3a, Wnt-7a, Wnt-10a, Wnt-10b, Wn-11 and Wnt-16 were significantly 
upregulated in M1 macrophages (Figure 13). Table 17 provides an overview of the Wnt-ligands 
expression in induced M1 and M2 polarized macrophages. 
 
Table 17. Wnt-ligands expression in induced M1 and M2 macrophages cell line RAW264.7. q-PCR 
analysis of several Wnt-ligands expression in RAW264.7 macrophages stimulated with INF-g (10 ng/mL) + 
LPS (100 ng/mL) and IL-4 (40 ng/mL) respectively. 
Wnt-ligand  
M1 macrophages RAW264.7  M2 macrophages RAW264.7 
24 h 48 h 72 h  24 h 48 h 72 h 
p-value p-value p-value  p-value p-value p-value 
Wnt-2a <0.01 ↑ - -  - - <0.05 ¯ 
Wnt-3a <0.01 ↑ - -  - - - 
Wnt-5a - - -  - - - 
Wnt- 5b - - <0.05 ¯  - - <0.01 ¯ 
Wnt-7a <0.01 ↑ - -  - <0.05 ¯ - 
Wnt-10a <0.05 ↑ <0.05 ↑ <0.05 ↑  - - - 
Wnt-10b <0.01 ↑ - -  - - - 
Wnt-11 <0.01 ↑ - -  - - - 
Wnt-16 <0.01 ↑ - -  - - - 
Gene expression is normalized to reference gene Rplp0 and presented as fold change relative to unstimulated controls. 
Statistical significance was determined by unpaired two-tailed Student’s t-test. ↑ = gene upregulation, ¯ = gene 
downregulation. 
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Figure 13. Wnt-ligand expression in M1 and M2 polarized macrophages. Gene expression analysis of 
Wnt-ligands in induced M1 and M2 macrophages cell line RAW264.7. M1 polarization was induced with 
INF-g (10 ng/mL) + LPS (100 ng/mL) and M2 polarization with IL-4 (40 ng/mL) for 24 h, 48 h and 72 
hours. Controls were left unstimulated. Gene expression is normalized to reference gene Rplp0 and 
expressed as arbitrary units (AU) n = at least 3 independent experiments for each time point. Data are 
expressed as mean ± standard deviation. Statistical significance was determined by unpaired two-tailed 
Student’s t-test *p ≤ 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001. 
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4.4 Wnt-ligands expression in epidermal and dermal fraction under type 1 and type 2 
immunity conditions in vivo 
In vitro we showed that Wnt-ligands were upregulated in keratinocytes and fibroblasts. In 
contrast, Wnt-ligands were downregulated in RAW264.7 macrophages but upregulated in M1 
polarized macrophages. Lastly, we aimed to verify the Wnt-ligands expression in vivo. Therefore, 
we examined our epidermal and dermal tissue fractions for the expression of specific 
Wnt-ligands, which functions have been partially investigated in vivo during wound healing 
(Wnt-2a, Wnt-5a, Wnt-5a, Wnt-10a and Wnt-11). Our results on the epidermal fraction showed 
that Wnt-10a was upregulated during the early inflammatory phase under type 1 immunity 
conditions (PWD1 and PWD3), whereas Wnt-5a, Wnt-5b and Wnt-11 were upregulated during the 
late inflammatory phase under type 2 immunity conditions (PWD12 and PWD14). In the dermal 
fraction, similar to the epidermal fraction, we found that Wnt-10a was upregulated under type 1 
immunity conditions. Whereas Wnt-5a, Wnt-5b and Wnt-11 were upregulated under type 2 
immunity conditions. However, Wnt-2a was the only ligand which showed a different expression 
pattern in the dermal fraction compared to epidermal, being upregulated during the late 
inflammatory phase under type 2 immunity conditions only in the dermal fraction (Figure 14). 
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Figure 14. Wnt-ligands expression in wounded epidermal and dermal fraction during early and late 
inflammatory phase of the wound healing. q-PCR analysis of Wnt-2a, Wnt-5a, Wnt-5b, Wnt-10a and 
Wnt-11 expression in the epidermal and dermal tissue fractions under type 1 immunity context 
(PWD1-PWD3) and type 2 immunity context (PWD12-PWD14). Gene expression is normalized to 
reference gene Rplp0 and expressed as fold change relative to unwounded epidermal and dermal tissue 
fractions (PWD0) respectively. n = at least 4 independent experiments for each time point. Data are 
expressed as mean value. Statistical significance compared to PWD0 was determined by unpaired 
two-tailed Student’s t-test *p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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5 DISCUSSION 
In this study, we explored the influence of prototypical type 1 and type 2 immune contexts on the 
canonical Wnt/ß-catenin signaling during wound healing. Both type 1/ type 2 immunity and 
Wnt-signaling have been shown to be required in this process for cell migration, differentiation 
and proliferation [81]. Furthermore, their combined activity is necessary for tissue repair [82]. So 
far, only a few investigations have focused on the relationship between immunity and Wnt-
signaling during wound healing. A recent study showed that TNFa was involved in the regulation 
of the canonical Wnt/ß-catenin signaling in epidermal stem cells [83]. Moreover, another study 
showed that TGFß (abundant in a type 2 immunity context) stimulated the activation of the 
canonical Wnt/ß-catenin signaling in fibroblasts [49]. These findings suggested that immunity and 
the canonical Wnt/ß-catenin signaling interact with each other. A better understanding of when, 
where and under which immunity conditions the Wnt-signaling and its ligands are active, will 
allow identifying time windows and targets to improve wound healing. For this, the connection 
between immunity and the temporal-spatial activation of Wnt-signaling and its ligands under 
physiological wound healing conditions needs to be explored.  
 
As a first approach to investigate the canonical Wnt/ß-catenin signaling under type 1 and type 2 
immunity we studied three of the most relevant cell populations during wound healing. The first 
cell population were macrophages which are key cells of the innate immune system regulating the 
pro- and anti-inflammatory responses during wound healing [84][85]. Then we chose fibroblasts 
and keratinocytes because they are the most abundant cells involved in the wound healing 
process, required for rebuilding the tissue and known to activate Wnt-signaling pathway [77] [23]. 
We found that in keratinocytes and fibroblasts the canonical Wnt/ß-catenin signaling was 
activated under type 2 immunity, whereas in RAW264.7 macrophages an activation under type 1 
or type 2 stimulation was not found. Furthermore, in polarized M1 and M2 macrophages we also 
did not find an activation of canonical Wnt/ß-catenin signaling. Our results in fibroblasts and 
keratinocytes are coherent with previous studies showing an activation of the canonical 
Wnt/ß-catenin signaling during the late phases of wound healing, in which type 2 immunity 
dominates [49][51]. Here, type 2 immunity might provide the right conditions downregulating 
pro-inflammatory signals in order to allow the restoration of the tissue. 
 
So far in keratinocytes it has been demonstrated in vitro and in vivo that the canonical 
Wnt/ß-catenin pathway is activated only via autocrine signaling [19]. We found that type 2 
cytokines also activate the canonical Wnt/ß-catenin signaling. This could be either due to the 
secretion of Wnt-ligands through type 2 immunity stimulation or through an unknown direct 
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mechanism using signaling downstream cytokine receptors. Future studies could explore this 
issue for example by utilizing siRNA or shRNA under type 2 immunity to silence Wls, which are 
required for the secretion of Wnt-ligands, to show whether autocrine activation mediates the 
effects of type 2 immunity on Wnt-activation. 
 
Our findings in cultured fibroblasts corroborated that TGFß stimulates the canonical 
Wnt/ß-catenin signaling [49]. However, dermal fibroblasts are a heterogeneous cell population 
showing different functional identities during wound healing depending on extrinsic signals [86]. 
This is of interest because the activation of the canonical Wnt/ß-catenin signaling results in 
different outcomes depending on which fibroblast subpopulation is activated in vivo [27]. For 
example, in a K14DNb-cateninER2 transgenic mice model it was shown that sustained epidermal 
Wnt/ß-catenin activation induced changes in the behavior of fibroblasts [27]. These changes, 
mediated through different paracrine signals, TGFß amongst them, induced in papillary 
fibroblasts the formation of ectopic hair follicles; in the same model it was also shown that 
reticular fibroblasts were influenced to remodel ECM and to differentiate into 
pre-adipocytes/adipocytes which proliferate and increase the thickness of the adipocyte layer [27]. 
Furthermore, there is evidence that fibroblasts exhibit a change in their heterogeneity in the 
transition to cell culture [86]. This means that we cannot assume that type 2 immunity activates 
canonical Wnt-signaling in all fibroblast subpopulations. Further studies are required to clarify the 
canonical Wnt/ß-catenin activation in the different fibroblasts subpopulations.  
 
Although several macrophage populations are known to be key regulators of wound healing, we 
found no activation of the canonical Wnt/ß-catenin signaling in RAW264.7 macrophages in vitro. 
The macrophages cell population is highly heterogeneous [10] and their function is shaped by 
local microenvironment signals [87]. It is possible that our findings have been biased by the 
absence of these important signals and by the fact that we used a homogeneous cell line in our 
experiments. We also cannot rule out an activation of Wnt/ß-catenin in primary cells or in vivo, as 
demonstrated in a 7 day-old wound granulation tissue of a Tcf reporter mice, in which canonical 
Wnt/ß-catenin signaling was activated in macrophages to regulate motility and adhesion during 
wound healing [88]. However, our in vitro experiments with macrophages provided a first insight 
into canonical Wnt/ß-catenin signaling under type 1 and type 2 immunity-controlled scenarios. 
We may need to analyze the activation of the canonical Wnt/ß-catenin signaling through other 
indicators (e.g., Axin2 expression or ß-catenin nuclear translocation in situ) to verify the absence 
of the canonical Wnt/ß-catenin signaling in macrophages. 
 
Our in vivo results showed, similar to the in vitro experiments, that the canonical Wnt/ß-catenin 
signaling was activated in the epidermal and dermal fractions only under type 2 immunity during 
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the late inflammatory phase of wound healing. Previous studies suggested that in epidermal stem 
cells, the canonical Wnt/ß-catenin signaling is also activated during the early phase under type 1 
immunity [83]. TNFα, a type 1 immunity cytokine secreted by macrophages, caused AKT 
phosphorylation and activation of canonical Wnt/ß-catenin signaling in hair follicle stem cells 
after extensive wounding [83]. In our work, we did not see this activation through the induction of 
Lef-1, perhaps because our epidermal fractions contained keratinocytes at different differentiation 
stages and also other cell populations like melanocytes or immune cells. Presumably, the amount 
of activated stem cells was too low in our fractions at the beginning of the wound healing to 
observe the activation of canonical Wnt/ß-catenin signaling. Another explanation could be the 
large size of the wound model (> 1 cm diameter) used in the study from Wang et al., which may 
induces an extensive type 1 immunity response [51]. 
 
Although the canonical Wnt/ß-catenin signaling was upregulated in the dermal fraction during the 
late inflammatory phase, its activation was found to be low compared to controls. It is possible 
that this low expression pattern of Lef-1 may be a result of mixing different cell populations 
within one dermal fraction including for example macrophages, which may not activate canonical 
Wnt/ß-catenin signaling, as suggested by our in vitro results. At the moment, fibroblasts are the 
only cell population within the dermis in which it is known that canonical Wnt/ß-catenin 
signaling is activated [51]. It remains to be verified if in other cell populations (e.g., pericytes, 
adipocytes, endothelial and different immune cell populations) whether canonical Wnt/ß-catenin 
signaling is activated in vivo. Further studies could establish a method to isolate the different cell 
types within the dermis using specific cell surface phenotype markers (e.g., papillary 
fibroblasts -CD90+CD39+CD26-, reticular fibroblasts -CD90+CD39+CD26+, 
preadipocytes -CD90+CD36+, pericytes -CD90+CD39+RGS5+) [24] to verify through q-PCR 
analysis or single-cell RNA sequencing the activation of the canonical Wnt/ß-catenin signaling 
and the expression of Wnt-ligands at different locations, time points and immune contexts during 
wound healing. 
 
Little is known about the expression and function of Wnt-ligands during wound healing. A 
specific expression pattern of the complex Wnt-ligand network has also not yet been established. 
However, existing data suggest that Wnt-ligands regulate tissue repair [70], with each ligand 
performing a different function which might be restricted to specific cell populations or time 
periods under either type 1 or type 2 immunity conditions. In vitro we found that keratinocytes 
upregulated Wnt-ligands (Wnt-2a, Wnt-3a, Wnt-5a, Wnt-5b, Wnt-7a, Wnt-10a, Wnt-10b, Wnt-11 
and Wnt-16) under type 2 immunity cytokine stimulation. This finding is line with previous 
studies showing in vitro that human keratinocytes and murine IFE stem cells were sources of 
Wnt-ligands [39]. In fibroblasts we found that some Wnt-ligands were also upregulated under 
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type 2 immunity (Wnt-2a, Wnt-5a, Wnt-10b and Wnt-11). Evidence has shown that epidermal 
Wnt-ligands are necessary to activate canonical Wnt/ß-catenin signaling in fibroblasts to restore 
the dermis after injury [70]. Furthermore, is also known that overexpression of epidermal 
Wnt-ligands potentiates hair follicle regeneration after wounding [34]. However, at the moment, it 
has been shown that fibroblasts are a source of a limited range of Wnt-ligands secretion: Wnt-1 
and Wnt-10b (fibroblasts differentiation into myofibroblast) [49], Wnt-2a (hair follicle 
regeneration) [51] and Wnt-5a (anti-apoptotic) [89]. This is mirrored by our in vitro experiments 
with fibroblasts. This may suggest that Wnt-ligand expression and function is cell specific. 
Moreover, we found that several Wnt-ligands (Wnt-2a, Wnt-3a, Wnt-7a, Wnt-10a, Wnt-10b, 
Wnt-11 and Wnt-16) were only upregulated in M1 polarized macrophages. A recent study on 
infarcted mouse-heart showed that macrophages expressed non-canonical Wnt-ligands [90]. 
Furthermore, it was shown that the loss of the Wnt-ligands secretion resulted in a shift toward 
M2-like macrophages, improving remodeling and function after myocardial infarction [90]. We 
speculate that macrophages modulate the activation of the canonical Wnt-signaling in neighboring 
cell populations through the secretion of Wnt-ligands and not only through cytokines [83]. 
 
Since the role of Wnt-2a [51], Wnt-5a [91][18], Wnt-5b [92], Wnt-10a [93] and Wnt-11 [55] have 
been explored during wound healing, we decided to investigate their expression in vivo under type 
1 and type 2 immunity conditions. We found that Wnt-5a, Wnt-5b and Wnt-11 were upregulated 
under a type 2 immunity conditions in both epidermal and dermal compartments during the late 
inflammatory phase. In our in vitro study, we found that Wnt-2a was upregulated in keratinocytes, 
fibroblasts and M1 macrophages. Wnt-2 was upregulated in vivo under type 2 immunity 
conditions, but it was exclusively expressed in the dermal fraction. Previous studies demonstrated 
that Wnt-2a is upregulated in fibroblasts at the late inflammatory phase, mediating hair follicle 
regeneration in a wound induced hair follicle neogenesis model [51]. Wnt-2a expression was 
triggered by Fgf9 from γδ T-cells in fibroblasts [51]. Further in vivo studies are needed to verify 
the expression of Wnt-2a in keratinocytes and M1 macrophages in relationship with its expression 
and function in fibroblasts subpopulations. 
 
It is known that pathogens and pro-inflammatory factors such as IL-1ß, TNF-a and LPS/IFN-g 
induce Wnt-5a expression in various cell types [94][95][96][97]. Moreover, it has been shown 
that Wnt-5a is upregulated in epidermal stem cells at the early inflammatory phase during wound 
healing [18]. Pro-inflammatory signals from the wound microenvironment are necessary for the 
initial secretion of Wnt-5a to facilitate cytoskeletal reorganization and cell migration in 
keratinocytes and fibroblasts through activation of both canonical and non-canonical 
Wnt-signaling pathways simultaneously [98]. Noteworthy, Wnt-5a also participates in regulating 
the extent of Wnt activation by antagonizing canonical Wnt/ß-catenin signaling through Wnt/Ca2+ 
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pathway and ß-catenin degradation during wound repair [98][99][100]. However, we found in 
vitro and in vivo that Wnt-5a was upregulated only under type 2 immunity cytokine stimulation 
and during the late inflammatory phase of wound healing. We assume that we did not detect 
Wnt-5a expression during the early inflammatory phase in our epidermal fraction due to the low 
number of Wnt-5a expressing stem cells. We will further address this issue in future studies. 
 
Although it is known that Wnt-5b is the closest Wnt-relative to Wnt-5a (amino acid identity 79%) 
[92], they exhibit distinct activities in coordinating cell proliferation and differentiation [92]. In 
our in vitro study, we found that Wnt-5b was upregulated in keratinocytes but not in fibroblasts 
under type 2 immunity cytokine stimulation. Furthermore, in vivo we found that Wnt-5b was 
upregulated in both epidermal and dermal fractions under type 2 immunity conditions. This 
suggests, that Wnt-5b activation in the dermal fraction might be stimulated through other 
cytokines/factors and not TGFß or IL-4. Another possibility may be the upregulation of this gene 
in other non-fibroblast populations in the dermis. 
 
Similar to Wnt-5a, Wnt-11 also activates the canonical and non-canonical Wnt-signaling. 
Furthermore, it is known that Wnt-5a and Wnt-11 cooperate with each other to regulate cell 
differentiation by suppressing canonical Wnt/ß-catenin signaling [98]. It is also known that 
Wnt-11 is involved in cellular apoptosis of myofibroblasts (in vitro) [55] and in wound 
remodeling with peaking its expression levels at PWD21 (in vivo) [52]. In vitro and in vivo we 
found that Wnt-11 was upregulated during type 2 immunity cytokine stimulation / late 
inflammatory phase, in keratinocytes / epidermal fraction and in fibroblasts / dermal fraction. 
Furthermore, Wnt-11 was also found to be upregulated in M1 macrophages. Further studies 
should verify the role of Wnt-11 in activated myofibroblasts during physiological and 
pathological wound healing conditions, as well as its role in the epidermis and macrophages. 
 
Wnt-10a was the only Wnt-ligand that we found upregulated during the early inflammatory phase 
under a type 1 immunity condition in the epidermal and dermal fraction. Previous findings 
showed that in absence of Wnt-10a the epithelial stem cells could not differentiate into hair 
follicles, sebaceous glands, nails and sweat ducts, due to the loss of the transcription factor KLF4 
[54]. Another study showed that the expression Wnt-10a has been identified in human keloid 
dermal myofibroblasts, but not in dermal fibroblasts [93]. Similar to this, we did not find an 
upregulation of this gene in fibroblasts from healthy skin in vitro. Further studies could verify if 
the activation of Wnt-10a in vivo is restricted to epidermal cells and furthermore, explore the 
expression in different fibroblast subpopulations and in fibrotic skin tissue samples. 
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In this study, we showed that the canonical Wnt-signaling and several Wnt-ligands were 
expressed in keratinocytes and fibroblasts mainly under type 2-like immunity situations. In 
macrophages we did not find canonical Wnt/ß-catenin signaling activation, but Wnt-ligands were 
found to be upregulated in polarized M1 macrophages. In line with our in vitro studies, we found 
in vivo that the canonical pathway was activated during the late inflammatory phase under type 2 
conditions. However, the Wnt-ligands expression was shown to be cell specific within the 
epidermal and dermal fractions and time specific during early or late inflammatory phase of the 
wound healing. Further studies should clarify the activation of canonical Wnt/ß-catenin signaling 
and their Wnt-ligand expression in different isolated cell populations and immunity contexts in 
vivo (see Supplementary results for strategies in the separation of distinct cell populations of the 
skin using FACS). These results may be compared to pathological skin wound healing models 
(e.g., chronic wounds in db/db mice or bleomycin induced fibrosis mice models) to clarify the 
physiological function of Wnt-ligands during cutaneous wound healing and how they become 
altered in disease and eventually allowing its modulation to achieve a better wound healing 
outcome and therapy options for wound disorders. 
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6 CONCLUSIONS 
This study aimed to analyze the activation of the canonical Wnt/ß-catenin signaling in important 
cell types of the skin that participate in wound healing (keratinocytes, fibroblasts and 
macrophages, non-polarized and within M1 or M2 polarization) in regards to type 1 and type 2 
cytokine stimulation and contexts. In vitro we showed that type 2 immunity cytokines stimulate 
the activation of canonical Wnt/ß-catenin signaling in keratinocytes and fibroblasts but not in 
macrophages. We also investigated canonical Wnt/ß-catenin signaling in M1 and M2 polarized 
macrophages and found that it was not upregulated. 
 
Then we defined the potential time points for specific Wnt-modulation in the epidermal and 
dermal compartment of the skin during wound healing using a full-thickness wound model in 
mice. We showed that canonical Wnt/ß-catenin signaling was activated in both epidermal and 
dermal fractions at time points (PWD12-PWD14) when type 2 immunity cytokines are 
upregulated. 
 
We then sought out to determine the role of type 1 and type 2 immunity on the expression of 
Wnt-ligands in vitro and in vivo. Type 2 immunity cytokines stimulated in vitro Wnt-ligand 
expression in keratinocytes and fibroblasts but not in macrophages. However, M1 polarized 
macrophages upregulated Wnt-ligands expression, although canonical Wnt/ß-catenin signaling 
was not activated. In vivo we further studied Wnt-ligand expression and found an upregulation in 
epidermal and dermal fractions mostly under type 2 immunity conditions. 
 
Both our in vitro and in vivo findings suggest that type 2 immunity conditions are required for 
Wnt-activation during tissue repair and that Wnt-ligands are differentially expressed at distinct 
cell types and time points in a specific manner. This study highlights the importance of 
understanding Wnt-activation and Wnt-ligand expression and function during wound healing to 
identify potential targets for therapeutic interventions. 
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7 PERSPECTIVES 
The epidermal and dermal tissue fractions used in this study contained different cell populations. 
To clarify Wnt-signaling activation in specific cells, future in vivo experiments could isolate 
different cell populations and subpopulations using magnetic activated cell sorting (MACS) or 
fluorescence activated cell sorting (FACS). 
 
In this work we studied Wnt-signaling and ligands in physiological conditions. The future 
investigation of Wnt-activation and Wnt-ligand expression in isolated cells during pathological 
wound healing conditions (e.g., chronic wounds in db/db mice or bleomycin induced fibrosis 
mouse models) could reveal genes that are over or under expressed which could contribute to 
pathology. 
 
To study the effect of type 2 immunity cytokines on Wnt-ligand expression, experiments utilizing 
cells transfected with siRNA or shRNA under type 2 immunity to silence Wls (required for the 
secretion of Wnt-ligands) could be conducted to show whether autocrine activation mediates the 
effects of type 2 immunity on Wnt-activation. 
 
To unravel the Wnt-ligand function in M1 polarized macrophages during wound healing, our 
experiments (but using isolated cells populations) could be conducted in transgenic mice, e.g., 
expressing Cre recombinase under control of a macrophage-specific promotor, with a Wnt-ligand 
being knocked out. Similar experiments can be conducted with fibroblasts and keratinocyte 
subpopulations. 
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9 APPENDIX 
9.1 Supplementary results  
 
Figure 15. Isolation of different skin cell populations from the dorsal skin of WT mice using 
fluorescence-activated cell sorting (FACS) . The scatter plot shows the gating strategy for the separation 
of distinct cell populations determined by staining with antibodies A) immune cells (anti-CD45+), B) 
endothelial cells (anti-CD45-CD31+), C) fibroblasts (CD45-CD31-CD326-) and D) epithelial cells (CD45-
CD326+).  
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